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Abstract
Radiation is one of the principal treatments for adults and children with brain tumors,
and is one of the oldest established treatments for tumors of all types. Currently, the lim-
iting factor for the use of radiation is the effect on normal tissue adjacent to the tumor.
Toxicity, including early and late effects from radiation, limits the dose administered to the
tumor and reduces the probability of cure. This work has three aims in its attempt to under-
stand and limit early radiation damage: characterize the role of the inflammatory molecules
tumor necrosis factor alpha (TNF) and intracellular adhesion molecule-1 (ICAM-1) in the
radiation response; evaluate the role of a novel anti-inflammatory agent as an interven-
tional therapy to limit the radiation-induced inflammatory response; begin to characterize
the acute damage following radiation using the shift in the gene expression.
Fluorescence intravital microscopy and a mouse cranial window model were used to
quantitatively measure: permeability of the blood-brain barrier, leukocyte adhesion, and
changes in vessel diameter following a single dose of 20-Gy localized cranial irradiation.
Immunohistochemistry and immunofluorescence staining were used to evaluate the num-
ber of activated astrocytes and the protein expression of TNF and ICAM-1. Antibodies to
TNF and ICAM-1 were administered to investigate their role in the early radiation response.
In addition, a novel anti-inflammatory agent, KZ-41, which is thought to work through NF-
κB was evaluated as a non-specific inhibitor to the early radiation response. Microarray
analysis was used to characterize the molecular shift that occurs in the brain at 2-hrs after
20-Gy radiation.
Our results show that the inflammatory molecules TNF and ICAM-1 are involved in
the early radiation response. Radiation induces an increase in permeability of the BBB
and in the number of adhering leukocytes at 24- and 48-hrs post-irradiation. It also causes
a decrease in the average diameter of arterioles at 48-hrs post-irradiation. Immunohis-
tochemistry showed a significant increase in the number of activated astrocytes at 24-
and 48-hrs post-irradiation, while immunofluorescence verified the expression of TNF and
ICAM-1 protein following radiation. When TNF expression was inhibited via specific anti-
bodies, all of the radiation-induced effects were abrogated. When ICAM-1 was inhibited
via specific antibodies, most of the radiation-induced effects were abrogated. Treatment
with ICAM-1 mAb in conjunction with radiation, completely inhibited the radiation-induced
vascular effects (BBB permeability, leukocyte adhesion, and arteriole diameter changes),
but did not inhibit activated astrocytes, however it did significantly reduce them compared
to radiation alone.
KZ-41 was evaluated as a potential agent for interventional therapy aimed at reducing
the radiation-induced inflammatory response. Using our radiation model, KZ-41 was found
to protect the vasculature in a manner similar to the specific antibodies to TNF or ICAM-1,
but was unable to prevent the radiation-induced astrocytic response. Permeability of the
BBB and leukocyte adhesion was inhibited, while there was no observed change in arte-
riole diameter at any time point. Immunofluorescence showed that treatment with KZ-41
limited the radiation-induced expression of ICAM-1 protein, but did not alter the expression
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of TNF protein. In addition, the number of activated astrocytes, following treatment with
KZ-41, was significantly higher than in radiation only animals.
Microarray analysis was used to investigate the shift in the genetic profile of the brain
following radiation. It was seen that, 2-hrs following irradiation, there is: a paracrine re-
sponse exists that is primarily initiated by chemotactic cytokines through the cytokine-
cytokine receptor interaction pathway; vascular and parenchymal damage whose response
can be distinguished when gene function is considered; and an alteration in genes known
to be related to neurological/neurodegenerative diseases.
Our overall aim is to elucidate the role of inflammation in the acute radiation response
and its effects on the microvasculature of the brain. Understanding this role will allow
for the development of treatment strategies to limit the acute radiation damage which we
believe will lead to a reduction in the long-term side effects of radiation.
v
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Chapter 1
Objectives
Radiation is one of the principal treatments for adults and children with brain tumors,
and is one of the oldest established treatments for tumors of all types. Currently, the limiting
factor for the use of radiation is the effect on normal tissue adjacent to the tumor. Toxicity,
including early and late effects from radiation, limits the dose administered to the tumor and
reduces the probability of cure. In the brain, toxicity arises from a combination of vascular
and parenchymal damage and varies in incidence and severity relative to dose and volume.
According to the Brain Tumor Progress Review Group, in order to overcome this normal
tissue toxicity, scientists should aim to “delineate the molecular, cellular, and physiological
processes leading to radiation-induced toxicity” [1]. Our overall hypothesis is that the early
radiation-induced damage to the microvascular network in the brain is primarily responsible
for the late effects observed in the normal tissue, and that by limiting the early damage,
the late effects can be reduced or prevented. In addition, we hypothesize that the early
damage to the microvasculature is due to the acute inflammatory response that is initiated
following radiation and that understanding the role of inflammation is key to determining a
way to reduce the side effects of radiation therapy and limit normal tissue damage.
Previously, our lab has shown that, in the brain and cremaster muscle, radiation in-
creases vascular permeability and leukocyte rolling and adhesion. Changes in vascular
permeability in the brain have been observed in a single dose (20-Gy) and fractionated
dose (2-Gy/day for 4 weeks; 40-Gy total) radiation regimen. Our lab has also shown that
there is an increase in the inflammatory molecules tumor necrosis factor-alpha (TNF) and
intracellular adhesion molecule-1 (ICAM-1), at the mRNA level, two hours after a single
dose and after the final fraction in the fractionated regimen. Others have confirmed the in-
crease in ICAM-1 expression following cranial radiation, and have also shown an increase
in interleukin-1β. We have also shown that the expression of ICAM-1 can be abrogated
following treatment with antibodies to ICAM-1, and that by abrogating ICAM-1 expression,
permeability and leukocyte adhesion can be inhibited. This work demonstrated a relation-
ship between the acute changes in the microvasculature and the inflammatory response
that is initiated following radiation. The current work aims to further elucidate the role of
the inflammatory response in the initiation and propagation of the acute microvasculature
changes by evaluating the role of TNF. This work also evaluates a novel anti-inflammatory
agent for use as a potential interventional therapy. In addition, this work evaluates the acute
damage following radiation by characterizing the gene profile using microarray analysis.
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1.1 Hypotheses
1. Brain irradiation causes an acute response which if unchecked creates a chronic
inflammatory microenvironment which amplifies radiation sequela. Treatment with
anti-TNF or anti-ICAM-1 agents during the early phase arrests this inflammatory re-
sponse and reduces radiation toxicity of the normal brain tissue.
2. KZ-41, a derivative of quinic acid that shows anti-inflammatory effects through the
NF-κB/ICAM-1 pathway, can be used to inhibit the inflammation-mediated acute ra-
diation effects.
3. The gene profile of the acute damage following radiation can give an insight into
the inflammatory, vascular, and parenchymal pathways that could be targeted for
interventional therapy to abrogate radiation-induced late effects.
1.2 Specific aims
1. Characterize the acute damage to the blood-brain barrier, following a single dose of
20-Gy localized cranial irradiation using a mouse cranial window model and histo-
logical methods and evaluate the effect of treatment with anti-TNF or anti-ICAM-1 in
conjunction with irradiation to abrogate inflammation-induced radiation damage.
Specific questions being investigated:
• What is the role of TNF and ICAM-1 in the acute changes observed following
radiation?
• Does inhibiting TNF affect the levels of ICAM-1 and visa versa?
• Is there a correlation between the increase in vascular permeability and leuko-
cyte adhesion? Does blocking either receptor, TNF or ICAM-1, disrupt this cor-
relation?
2. Evaluate the effectiveness of KZ-41 as an interventional therapy for acute radiation
damage to the blood-brain barrier following a single dose of 20-Gy localized cranial
irradiation and compare to the response observed from the direct inhibition of the
inflammatory molecules TNF and ICAM-1 via antibodies.
Specific questions being investigated:
• Is KZ-41 able to inhibit the radiation-induced vascular changes known to be
effected by TNF and ICAM-1?
• Does KZ-41 affect the levels of TNF or ICAM-1 following localized cranial radia-
tion?
• If KZ-41 works through the ICAM-1 pathway only, does it decouple the vascular
response from the astrocytic response?
2
3. Investigate the acute inflammatory, vascular, parenchymal, and neurostructural changes
in the brain following radiation damage by characterizing the gene response using mi-
croarray gene expression analysis.
Specific questions being investigated:
• Is there a paracrine response that occurs?
• Can we distinguish between parenchymal and vascular damage?
• Are there early signs of neurostructural damage?
3
Chapter 2
Introduction
2.1 Use of radiotherapy in the clinic to treat brain tumors
Each year approximately 50,000 people are diagnosed with a primary brain tumor and
another 180,000 people develop brain metastases. The outcome of a patient diagnosed
with a brain tumor depends on a variety of factors including: the location of the tumor,
the type of tumor, age at time of diagnosis, and overall health [2]. The most common se-
quence of treatment for a brain tumor consists of surgical resection followed by adjuvant
radiation therapy and chemotherapy when indicated. Gross removal of the tumor is of-
ten the best treatment; however, due to the intricate nature and complexity of the brain,
surgery may not be feasible or is likely to be incomplete, necessitating the use of radiation
therapy, chemotherapy or a combination of the two. Chemotherapy is used to treat brain
tumors, but often fails due to a lack of sensitivity of the tumor to a given agent or because
of the barriers (blood-brain barrier and blood-tumor barrier) in the brain, that limit therapeu-
tic concentrations of a chemotherapeutic agent from reaching the tumor. Radiation is the
most effective non-surgical therapy for brain tumors and is often the most effective adju-
vant therapy after surgery. The effectiveness of radiation therapy is offset by its deleterious
effects on normal tissues. Patients treated with radiotherapy risk neurologic, endocrine,
and cognitive dysfunction resulting from damage to the microvasculature and parenchyma
[3, 4]. In recent years, there have been significant advances in the use of radiation as a
treatment including hardware and software, aimed at improving tumor control and minimiz-
ing side effects. The advances include conformal, intensity-modulated and proton beam
radiation therapy. All of these methods rely on 3D treatment planning concepts that have
the goal of conforming dose to the tumor and minimizing dose to normal tissue. Hard-
ware advances include the use of multi-leaf collimators to tailor the shape of the radiation
field to a target volume, which has dramatically reduced the dose received by the normal
tissue. The main advance in software has been the ability to incorporate the data from
multiple imaging modalities (CT, MRI, and PET) into a single treatment planning system to
aid in pretreatment evaluation and tumor delineation. All of these advances in the field of
radiation therapy have raised the hope of more effective treatment; however, side effects
continue to limit the value of radiotherapy in some patients.
There are two classes of brain tumors: primary and metastatic. Primary brain tumors
are tumors that arise from the cells of the central nervous system (CNS), predominately
from the glial cells (56% in ages 0-14 years, and 36% in all ages) [5]. Tumors of glial origin
include glioblastomas, astrocytomas, oligodednrogliomas and ependymomas. Metastatic
tumors are those that begin as cancer in one place and then spread to another. The most
common types of metastatic cancers that spread to the brain are breast cancer and lung
cancer. Currently, in children with primary CNS tumors diagnosed between the ages of 0
4
and 14 there is a 5 year survival rate of 66%. Of these 66%, it has been reported that up
to 86% will survive out to 15 years post-diagnosis [6]. With these advances in our ability to
effectively treat tumors, it is becoming more and more important to identify the necessary
procedures to limit the side effects of radiation treatment.
In the clinic, there are a variety of ways that radiation is used for treatment. The most
common type of radiation treatment is external beam irradiation, where the radiation source
is outside the body and must penetrate the body to reach its target. Other types of radiation
therapy include: internal radiation or brachytherapy where a radioactive pellet is implanted
at a specific site to treat a local area; systemic radiation where a radioactive source is
injected into the veins and travels throughout the body delivering radiation; and interopera-
tive radiation where the target is surgically exposed and then administered radiation using
an external beam. For brain tumors, external beam radiation is used. However for the ra-
diation to reach the tumor; it must pass through surrounding normal (or non-tumor) tissue,
Figure 2.1. When the radiation passes through the normal tissue it damages the tissue,
which can lead to side effects. The aim of the current work is to identify a way to minimize
the damage to normal tissues while not compromising the effectiveness of radiation as a
treatment for brain tumors.
2.2 Side effects of radiotherapy and current treatments
Radiation-induced CNS injury is usually divided into three categories: acute (within
days), early (1-6 months post treatment), and late [7]. Late radiation damage has been
identified through changes in neuropsychometric, neuroendocrine function, or vascular
events, Figure 2.2, that may result in ischemia[8]. Brain tumor patients treated with cra-
nial radiation have been reported to suffer from late-term side effects such as decreases
in motor/sensory coordination, altered hypothalamic hormone levels, delayed growth and
development, IQ deficits, memory loss, behavioral problems, and lower academic achieve-
ment [4], Table 2.1. These late-term effects are common in tissues with limited potential
for self-renewal, such as in the CNS [3]. The observation of late radiation damage is
often made in adults and children months or years after radiotherapy; however, we now
know that the onset of microvascular changes after radiotherapy is immediate [9, 10]. This
chronological division of radiation injury does not necessarily reflect a mechanistic dispar-
ity [11, 12, 13]. A central hypothesis to our work is to understand the mechanisms involved
in early radiation damage to better understand the development of the late damage. In this
work, the role of the inflammatory response in the acute radiation damage is characterized.
During and after radiation, brain tumor patients are often treated with an array of
medicines in an effort to relieve the acute side effects of radiotherapy, (Table 2.1), in-
cluding steroids, diuretics to reduce brain swelling and pressure, anti-convulsants to re-
duce seizures, and pain medication. The main such treatment are corticosteroids such
as dexamethasone. Dexamethasone is a glucocorticoid steroidal hormone that has anti-
inflammatory and immunosuppressant effects. It is administered to reduce edema and
brain swelling; however it can produce side effects such as fungal infections, muscle weak-
ness, fluid retention, and weight gain via increased appetite. All of the drugs administered
are used to treat the physical side effects of radiation, and make the patient more com-
fortable. They are not intended to protect the irradiated tissue from damage, although
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Figure 2.1: Radiation dose map.
Treatment plans are designed with the goal of maximizing radiation to the tumor volume,
avoiding sensitive structures, and minimizing the dose to the non-tumor tissue. This image
shows the treatment plan of composite whole brain and posterior fossa irradiation for a
medulloblastoma. The colored boundaries are progressively lower doses of radiotherapy,
with magenta = 55·8 Gy; light blue = 36·0 Gy; and green = 36·0 Gy. Image from Mulhern
et al. “Late neurocognitive sequelae in survivors of brain tumours in childhood”, Lancet
Oncol, 5: 7, 2004, Copyright (c) 2004 Elsevier, with permission from the publisher.
Figure 2.2: Late effects of radiation.
Using MR imaging, clinical late term effects can be observed. (Left) example of left poste-
rior cerebral radiation-induced vasculopathy in a patient with low-grade glioma after radia-
tion therapy and (Right) an example of brainstem and cerebellar radiation-induced necrosis
in a patient with ependymoma (white arrows). Image courtesy of Dr TE Merchant, St Jude
Children’s Research Hospital
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Table 2.1: Clinical side effects of radiotherapy.
Acute Long-term
Nausea/vomiting Neurologic:
Edema Hearing loss
Fatigue Loss of vision
Immune suppression Motor/sensory coordination
Loss of appetite
Hair loss Endocrine:
Dermatitis Growth and development
Hypothalamic hormone levels
Cognitive:
IQ deficits
Memory loss
Attention disorders
Behavior
Academic achievement
treatment with dexamethasone has been shown to reduce permeability of the blood-brain
barrier (BBB) [14, 15] and inhibit radiation-induced up-regulation of ICAM-1, P-selectin,
and E-selectin [16].
2.3 How radiation damages cells
X-rays are the primary type of ionizing radiation used in the clinic. The x-rays are pro-
duced extranuclearly by accelerating electrons to a high energy and then stopping them
abruptly in a target, most commonly of tungsten or gold [17]. For radiotherapy, linear ac-
celerators are commonly used to produce the x-rays at megavoltage energies. The energy
range used in clinical therapy is usually from 6-MV to 20-MV, with the higher energies used
to obtain deeper penetration into the tissue.
The x-rays used in radiotherapy have enough energy to ionize atoms along their path
through the tissue. As the x-rays traverse through the body, they interact with atoms along
their path causing the ejection of electrons through one of three processes: photoelectric
effect, Compton scattering or pair production. When the electrons are ejected, they form
free radicals, primarily hydroxyl radicals, which can then damage the cells by causing single
strand or double strand breaks in the DNA [18, 19]. Single strand breaks can often be
repaired when DNA is synthesized during cell replication. Double strand breaks, however,
cannot be easily repaired and often result in cell death.
Following radiation, there are two types of damage that can occur, direct and indirect,
Figure 2.3. At the cellular level, direct radiation damage is when the DNA of a cell is
damaged directly by the penetrating radiation beams, most likely from the ionization of an
oxygen molecule. Indirect damage is when a different molecule, usually water, is ionized
creating free radicals that are able to damage the DNA of a cell [17]. At the system level,
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Figure 2.3: Direct versus indirect radiation.
Schematic of how radiation works. radiation enters the body, and primarily interacts with
water molecules forming free radicals that then interacts with cells causing DNA damage,
however there can also be direct damage to the DNA by the radiation. Once the DNA is
damaged, the cell can either repair itself, or it will mutate and induce a biological response.
This biological response can be death, or a genetic, somatic, or teratogenic effect. Note
the time frame over which the damage can occur.
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direct damage is inflicted on a given cell by the ionizing radiation, while indirect damage is
when a nearby cell is damaged initiating a sequlea of events that includes an inflammatory
response and subsequently leads to damage of surrounding cells. Direct damage from
ionizing radiation, is very difficult to prevent, but steps can be taken to minimize the indirect
damage.
Organs are comprised of both vasculature and tissue; however, in the field of radi-
ation research there is an ongoing controversy as to which, vasculature or issue, is the
more significant source of radiation damage. Otsuka et al [20] used neutron radiation of
mercapto-undecahydro-dodecaborane (BSH) to selectively irradiate the vasculature of the
brain, and then looked at neuronal precursor cell populations. They showed that when
only the vasculature was irradiated there was less neuronal precursor cell loss indicating
that neuron precursor cells are damaged more by direct radiation damage, than by indi-
rect damage from the vasculature. Schuller et al [21] also showed that following selective
radiation, administered similarly to Otsuka et al [20], there was no change in crypt stem
cell loss compared to whole body radiation, indicating that it is direct not indirect damage.
In contrast, Lyubimova et al [22] used the radioprotector Gammaphos, that does not cross
the BBB, to show that when the vasculature is protected during radiation, the amount of
necrosis, and endothelial cell loss, was significantly reduced. This indicates that the vas-
culature plays a primary role in radiation damage in the brain. Others have also shown
that damage to the vascular endothelium is the primary event leading to late development
of white matter necrosis [23]. In addition, there is also evidence that the extent to which
vascular damage plays a role may depend on the location or organ being irradiated [24].
So although there is an ongoing controversy as to what role radiation-induced damage to
the microvasculature network has on observed effects overall, there is agreement that it
does play a part and as such, should be investigated.
2.4 Sensitivity to radiation damage
The sensitivity of an organ to radiation damage depends on: the inherit sensitivity
of the individual cells, the kinetics of the tissue as a whole, and the way the cells are
organized. In general, the tolerance of an organ to radiation depends on the ability of
the clonogenic cells to maintain a sufficient number of mature cells suitably structured to
maintain the function of the organ. As such, the total dose of radiation that can be tolerated
by an organ depends on the volume of the organ receiving radiation. The amount of time
between radiation insult and the expression of damage in the tissue/organ depends on the
population kinetics of the organ. The population kinetics are based on the normal lifespan
of the mature cells in the organ, and the amount of time it takes for new cells to mature to
a functional state [17].
The radiosensitivity of an individual cell is related to the metabolic state of the cell;
cells that have a higher rate of proliferation, such as tumor cells, are more radiosensitive
than less proliferative cells such as neuronal or endothelial cells. It is this characteristic
that makes radiotherapy a successful treatment for tumors. However, normal tissue is also
damaged by radiation, but at a lower rate than tumor cells.
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Table 2.2: Classification of cell and tissue radiosensitivity.
Radiosensitivity Examples Characteristics
High
radiosensitivity
Cell: crypt cells, basal cells,
Type A spermatogonia
erythroblasts, lymphocytes
Tissue: lymphoid, marrow,
spermatogenic and ovarian
epithelium
Rapidly dividing,
undifferentiated; does
not differentiate
between divisions
Relatively
radiosensitive
Cell: myelocytes,
intermediate spermatogonia
Tissue: epidermal
epithelium, bladder
epithelium, optic lens, gastric
gland, and ureteral epithelium
Actively dividing;
some differentiation;
differentiates between
divisions
Intermediate
radiosensitivity
Cell: Endothelial cells,
fibroblasts cells Tissue:
interstitial connective,
neuroglial connective, fine
vasculature, bone tissue,
cartilage
Irregularly dividing,
moderate mitotic
frequency
Relatively
radioresistant
Cell: Parenchymal cells of
the liver, fine vasculature
Tissue: Mature cartilage or
bones, salivary glands,
respiratory organs, kidneys,
liver, pancreas, thyroid,
adrenal and pituitary glands
Do not normally
divide, but retain
capability of division;
differentiated
Highly
radioresistant
Cell: Nerve cells, muscle
cells, Erythrocytes (RBC’s)
Tissue: Muscle, Brain, Spinal
Cord
Do not divide;
differentiated
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Ionizing radiation can damage any type of cell in the body, however, the sensitivity
of a cell to damage by radiation depends on multiple factors including the type of cell and
the phase of the cell cycle that particular cell is in. Table 2.2, shows the basic relative ra-
dioresistance of different cells based on direct radiation effects. Endothelial cells, the cells
that comprise the vasculature of the brain, are considered intermediate in radiosensitivity,
while neuronal cells are some of the most radioresistant cells in the body. In addition to
cell type, the phase of the cell cycle that a cell is in affects its radiosensitivity. Cells are
the most sensitive during mitosis (M phase) and RNA synthesis (G2), less sensitive during
the pre-DNA synthesis period (G1), and least sensitive during DNA synthesis (S Phase)
[18]. If a cell is physically damaged by radiation, it can repair itself, mutate, or die which
leads to the biological expression (or effects) of the damage. This biological expression
may appear within seconds to minutes of damage, or it may take months to years for an
effect to be observed.
The conventional approach to radiotherapy is to administer multiple small doses of
radiation to a region over a period of weeks as a way to limit damage to normal tissues
and to increase damage to the tumor. This works for four reasons: 1) it allows time for
the repair of sublethal damage to normal cells, 2) it allows for the re-population of cells,
3) it allows a re-assortment of cells within phases of the cell cycle, and 4) it allows for the
reoxygenation of the region [17]. By allowing the normal (non-tumor) cells time to repair
after insult, there is an increased chance that the cell will survive, and if the interval is
long enough, repopulation of a cell type can occur. As the sensitivity of a tissue depends
on the organ maintaining enough mature functioning cells, allowing time for the injured
cells to repair themselves increases the tolerance of an organ to radiation. In addition, as
radiation relies on oxygen to create the free radicals that damage a cells’ DNA, allowing
time for reoxygenation means that when a subsequent dose of radiation is given, you are
not reducing the overall effectiveness of the radiation to kill the tumor cells. Also, as tumor
cells are highly proliferative, allowing time between radiation doses increases the number
of cells that will be in the most sensitive phases (M and G2) of the cell cycle.
2.5 The brain: components and response to radiotherapy
The brain plays an important role in coordinating motion, interpreting, and storing
sensual information. Such complicated functions demand a continuous and reliable supply
of oxygen and nutrients (e.g. glucose). The overall design of the microvascular network in
the brain is a function of metabolic stimuli, biochemical growth factors, feedback control,
external stimuli, and hemodynamic parameters [25]. The network has a versatile architec-
ture that responds dynamically to the functional demands of the tissue, and is used by the
immune system to monitor and survey its surrounding tissue and as the highway through
which relief and repair is delivered. The microvascular network is defined as a series of
interconnected arterioles, venules, and capillaries with low Reynolds numbers and large
surface areas, which provide an optimal environment for the supply of oxygen, nutrients,
removal of waste products and interaction of blood cells (i.e., red blood cells, white blood
cells, platelets, etc.) with endothelial cells [26, 27]. The diameters of the blood vessels
range in size with the arteries being 10 - 125µm, venules 20 - 100µm, and capillaries 7 -
20µm, with the blood velocity varying between 100 - 2000µm/s within these vessels [28].
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This process is more complex in the brain because of the presence of the blood-brain
barrier (BBB), Figure 2.4. The BBB is responsible for protecting the parenchyma of the
brain at the vascular interface, by regulating the movement of substances between ves-
sels and tissue. The BBB is comprised of endothelial cells that are tightly adhered via
tight junction proteins such as occludin. In the brain’s vasculature, these tight junctions
eliminate the paracellular pathway for hydrophilic solutes, which is otherwise available in
vasculature outside of the brain [29, 30]. The endothelial cells that comprise the BBB also
have very few pinocytotic vesicles [31] and fenestrations that are common in non-cerebral
vasculature, and contain more mitochondria [32] than normal endothelial cells, indicating
more specific active transport of nutrients from the blood, rather than passive transport.
The BBB is regulated by the presence of astrocytes and pericytes [33, 34, 35]. Pericytes
are phagocytic cells that remove foreign bodies, while astrocytes are star-shaped glial cells
whose end-feet surround the endothelial cells strengthening the tight junctions and provid-
ing another layer of protection for the parenchyma from substances in the blood. When the
barrier between the vascular supply of the brain and the CNS parenchyma is disrupted,
excess extravasation of proteins, biologic-response molecules (e.g. growth factors, cy-
tokines, and clotting factors), inflammatory cells, and therapeutic drugs can damage the
brain [36, 37, 38, 39]. The disruption of the BBB has been identified as a consequence
of various diseases/injuries such as multiple sclerosis, ischemia, HIV, hypertension, brain
tumors, CNS injury and radiation exposure [39, 40, 41, 42, 43, 44, 45, 46]. Following radi-
ation, the BBB is known to be damaged. There is opening of the tight junctions leading to
increased vessel permeability, up-regulation of adhesion molecules leading to increased
leukocyte activity, astrocytes and pericytes pull away from the endothelial cells, Figure
2.4, Table 2.3. The reported radiation-induced late effects on the microvasculature include
telangiectasias, dilation, vessel wall hyalinization, and thickening with fibrinoid necrosis
[47, 48]. Damage to any part of the BBB may compromise its integrity and ability to protect
the parenchyma.
We and others have demonstrated that there is an increase in BBB permeability fol-
lowing cranial radiation [9, 70, 71, 72]. This increase in permeability is due, at least in part,
to changes in the integrity of the tight junctions between adjacent endothelial cells and by
the formation of vesicles in the endothelial cells. Yuan et al have shown that there is a size
dependent increase in BBB permeability 24-hrs after cranial radiation [9]. Yuan et al also
showed that there is a time-dependent difference in the mechanism of BBB permeability.
In the acute phase following radiation, alterations of the tight junctions have been observed
as the mechanism responsible for the BBB permeability increase, while in the late phase,
the primary mechanism appears to be vesicular formations [70]. The alterations of the tight
junctions are thought to be caused by the up-regulation of intracellular adhesion molecule-
1 (ICAM-1), which is known to induce cytoskeletal reorganization. The effect that radiation
has on endothelial cells themselves and the role they play in initiating/sustaining damage
is of great interest. It has been shown that when irradiated, endothelial cells undergo
apoptosis at a higher rate than other cells, in vitro and in vivo [50, 51, 73].
Endothelial cells play a unique role in maintaining the body’s physiological balance
or homeostasis, controlling the movement of substances across the blood compartment
into the different tissues and organs with varying demands and function [74]. The en-
dothelial cells also play an important immune function through leukocyte surveillance and
extravasation by regulating adhesion integrins and cytokine production [75]. We and others
have shown that there is an increase in leukocyte activity following radiation [76, 77, 78,
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Figure 2.4: Cartoon depiction of the normal and damaged BBB.
A cartoon depicting a cross section of brain parenchyma showing the structure of the blood
brain barrier (BBB) and the damage induced by radiotherapy. (Upper) Normal BBB show-
ing: intact tight junctions; lack of vesicles; astrocytes and pericytes abutting the endothelial
cell providing additional barrier support. (Lower) Damaged BBB; astrocytes and pericytes
have pulled away from the endothelial cell; a leukocyte has adhered to the endothelial cell
surface; loss of tight junction integrity; and vesicle formation. The damage to the BBB
results in the extravasation of molecules out of the blood vessel and into the extracellular
space.
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Table 2.3: Radiobiologic side effects of radiotherapy.
Reported Side Effect Reference
Increased vessel permeability [49, 50, 51]
Altered expression of adhesion molecules [52, 16]
Vascular constriction [10]
Platelet aggregation [53]
Endothelial detachment from the basement membrane [53]
Cytoskeletal reorganization [54]
Decreased vessel density [55]
Altered cytokine expression [56, 57, 58]
Inhibition if angiogenesis [59]
Hypoxia [60, 61]
Loss of neuronal precursor cells [23, 62, 63]
Decrease in cell proliferation [64]
Apoptosis [64, 51]
Thromboses [65]
Demyelination [66, 7]
Necrosis [66, 67, 68]
Astrogliosis [69, 58, 70]
14
30, 9, 26]. When initially inflamed, endothelial cells will up-regulate numerous adhesion
molecule receptors, L-selectin, E-selectin, and P-selectin, on their surface. The function
of these receptors is to weakly attract leukocytes, which causes them to roll along the en-
dothelium initiating the first step in leukocyte-endothelial interactions. The second step in
leukocyte-endothelium interactions is the adherence of the leukocytes to the endothelium,
a rate-controlling step in the inflammatory cascade, which is mediated by the upregula-
tion of adhesion molecules (ICAM-1), intracellular adhesion molecule-2 (ICAM-2), vascu-
lar cell adhesion molecule-1 (VCAM-1), and platelet/endothelial cell adhesion molecule-1
(PECAM-1) on the endothelium [79]. Yuan et al have shown that following cranial radiation,
there is an increase in the expression of ICAM-1, E-selectin, and P-selectin, and that the
expression of these molecules is time-dependent. It is known that certain cytokines are
responsible for an increase in leukocyte adhesion such as: tumor necrosis factor-alpha
(TNF), Interleukin-1, Interleukin-4, and Interferon-γ [80, 79].
A decrease in arteriole diameter is one of the reported manifestations of radiation-
induced damage to the microvascular network [10]. The mechanisms of vasoconstriction
are not completely understood, but include: alterations in calcium signaling from the as-
trocytes, changes in nitric oxide levels, constriction of the smooth muscle cells, hematocrit
variations, and over-proliferation of endothelial cells [81, 17, 82, 83, 84]. When vasocon-
striction occurs, the amount of oxygen reaching an area is reduced creating a state of
hypoxia and inducing the up-regulation of hypoxia inducible factor-1α (HIF-1α). Hypoxia
has been shown to activate inflammatory mediators [85, 86], including ICAM-1, on en-
dothelial cells, and promote vascular remodeling/angiogenesis [85] and vascular perme-
ability [60, 87] via the up-regulation of vascular endothelial growth factor (VEGF) and its
receptors. Hypoxia also creates a shortage of oxygen free radicals, which is primarily how
ionizing radiation damages DNA, which can increase the radioresistance of nearby cells
[61, 88, 89, 90].
Astrocytes are the most abundant cells in the CNS, outnumbering neurons 10 to 1
[91, 92]. They have many roles in the brain including helping to maintain the integrity of
the BBB, supplying nutrients to neurons, regulating ion concentrations in the extracellular
space, signal transmission and controlling vascular hemodynamics [93]. In response to
CNS injury, astrocytes will become activated and respond by hypertrophy of their cellular
processes and an increased production of the intermediate filament glial fibrillary acidic
protein (GFAP) [94, 95]. Astrocyte activation, or astrogliosis, can persist from weeks to
months to years after an injury. Previous studies have shown that astrogliosis occurs
following a single dose [69] or fractionated doses of radiation [70] and that astrocytes can
produce the inflammatory markers tumor necrosis factor-alpha (TNF) and ICAM-1 which
are also known to be up-regulated following radiation [57, 96]. Whether radiation-induced
astrogliosis is caused by direct ionization damage or due to the breach in the BBB exposing
the parenchyma to noxious substances and inflammatory cytokines is unclear. However,
activated astrocytes have been shown to secrete inflammatory agents [97, 98] which, in
turn, could amplify endothelial cell and microvascular damage.
The neurons are less abundant than glial cells in the parenchyma and are responsible
for transferring signals across the brain’s functional systems [99, 38]. Neuronal cells are
responsible for processing and transmitting cellular signals through chemical and electri-
cal synapses. In the brain, neuronal axons are usually covered with an insulating layer
formed by glial cells, known as oligodendrocytes, to form the so called myelin sheath.
15
This sheath increases rates of signal transmission and confines the signal to the neu-
ron thus conserving metabolic energy. The demyelination of neurons can be dire and is
seen in neurodegenerative autoimmune diseases such as Multiple sclerosis, Transverse
myelitis, Guillain-Barre Syndrome, and adrenoleukodystrophy. In these diseases the in-
flammatory cells are able to penetrate the BBB and destroy the myelin surrounding the
axons. Demyelination and myelin thinning have been reported in the CNS following radia-
tion [100, 101, 102, 103]. In addition, Felts et al. has also shown prolonged increases in
BBB permeability can induce demyelination of neurons [104].
Mature oligodendrocytes, the glial cells that lay the myelin sheath insulating the neu-
ronal axons in the brain, are derived from the oligodendrocyte type 2 astrocyte (O-2A)
progenitor cells. A decrease in O-2A cell populations limits the capacity to form new oligo-
dendrocytes. After radiation, it has been shown that there is a decrease in the number of
clonogenic O-2A cells as well as oligodendrocytes. Oligodendrocytes have been shown
to undergo apoptosis via the p53 pathway, while the mechanism of cell loss of O-2A cells
is unknown. It has also been shown that oligodendrocyte cell death can be induced by
TNF, which is up-regulated following radiation, thus adding an additional toxicity to the
cells following radiation exposure. The loss of the O-2A cells following radiation has been
proposed as a cause for the observed demyelination [105].
As is expected, long-term damage from radiotherapy involves the many different cell
types found in the brain as well as circulating cells. Figure 2.5 is a graphical depiction of the
interaction of the components of the brain and their role in observed damage following cra-
nial irradiation. The current work focuses on the acute vascular and astrocytic responses
to radiation damage, with the goal of understanding the mechanism of this damage so
that an interventionl therapy can be used to minimize the response. It is hypothesized that
by minimizing the acute vascular and astrocytic response the long-term response can be
abrogated.
2.6 Radiation-induced inflammation and current clinical treatments
The up-regulation of adhesion molecules plays an important role in the inflamma-
tory response of normal vasculature and facilitates the recruitment, transendothelial mi-
gration and proliferation of inflammatory cells in the extravascular compartment [106, 107,
108, 109]. TNF is a soluble 17 kDa pro-inflammatory cytokine molecule that binds to two
distinct receptors, TNFR1 (p55) and TNFR2 (p75). It is primarily produced by activated
macrophages and monocytes, however, in the brain; all brain cells including endothelial
cells have the ability to produce TNF in response to stimulus [110, 111]. TNFR1 is known
to be ubiquitously expressed on all mammalian cells while TNFR2 is largely confined to
endothelial cells. TNF is known to be involved in leukocyte adhesion, cell permeability,
edema, acute and chronic inflammation, and the release of other inflammatory cytokines
[112, 113]. Binding of TNF to its receptors has been implicated in the activation of nuclear
factor–kappa B (NF-κB), which in turn switches on the synthesis of adhesion glycoproteins
such as ICAM-1 [80], Figure 2.6. In addition to activating NF-κB, TNF can induce cy-
toskeletal reorganization leading to the up-regulation of P-selectin from the Weibel-Palade
bodies. When inactive, P-selectin is internalized, but when activated it moves to the cell
surface where it is a primary molecule responsible for cell rolling, along with E-selectin.
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Figure 2.5: Pathophysiology of radiation-induced damage.
This is a schematic of the different cell types in the brain and their hypothesized roles in
the induction of radiation-induced lesions in the brain. Adapted with permission. G. Steel,
Basic Clinical Radiobiology 3rd edition, Oxford University Press, p. 37. Copyright (c) 2002.
Arnold Publishers.
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Figure 2.6: Radiation-induced cellular response.
Diagram of the main inflammatory molecules known to be induced by radiation, and how
they interact.
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TNF has been shown to be up-regulated at the mRNA level following single and fraction-
ated radiation [57].
ICAM-1 is a cell surface glycoprotein that is up-regulated by inflammatory stimuli and
plays a role in a variety of diseases by interfering with normal immune function [109].
It is constitutively expressed in the brain by endothelial cells, astrocytes, and microglia
[109]. ICAM-1 is the primary adhesion molecule responsible for the transendothelial mi-
gration of leukocytes from vessel to surrounding tissue by inducing cytoskeleton restruc-
turing creating openings between adjacent endothelial cells [114]. These openings allow
not only leukocytes, but any substance that is smaller than the opening created to enter
the parenchyma from the blood. Previous studies have shown that radiation induces the
up-regulation of ICAM-1 gene and protein expression in the brain [57].
NF-κB is a transcription factor that plays significant roles in cell proliferation, apopto-
sis, stress response, inflammation, and other cellular processes. Following radiation, the
activation of TNF and the creation of reactive oxygen species (ROS), lead to the activation
of the IκB kinase (IKK) which then degrades the inhibitor of κB (IκB). The degradation of
IκB leads to the release of two NF-κB subunits, p65 and p50. The p50 subunit acts as
a regulatory control and re-inhibits NF-κB by promoting IκB, while the p65 subunit travels
to the nucleus to activate the transcription of genes with binding sites for NF-κB activity.
Genes that are known to be regulated through NF-κB include ICAM-1, VCAM-1, and E-
selectin [115, 116]. Further, there is evidence that TNF and NF-κB are major targets of
commonly used anti-inflammatory drugs such as glucocorticoids and aspirin [80].
2.7 KZ-41
KZ-41 is a potent analog of quinic acid, which is an active ingredient in hot water
extracts of the herbal cat’s claw (uncaria tomentosa). Hot water cat’s claw extracts (e.g.,
C-Med-100® and Activar AC-11®) have very low alkaloid content (<0.5%) and yet retain
significant anti-inflammatory activity, which can be attributed to the quinic acid carboxy alkyl
ester [117]. Studies have shown that the anti-inflammatory activity of cat’s claw extracts
is through the inhibition of NF-κB, and that this inhibition is coming from the quinic acid
carboxyl alkyl ester found in the extract [118]. Aqueous extracts from the bark or root bark
are used therapeutically in a diversity of diseases including allergy, arthritis, chemotherapy
side effects, cancer, bacterial/fungal infections, gastrointestinal inflammation and gastric
ulcers [119, 120, 121, 122, 123]. Oral administration of C-Med-100® to humans at doses
of 250-750 mg daily has been shown to enhance immune cell response and DNA repair
[124, 125, 126].
Preliminary studies, unrelated to the current work, indicate that KZ-41 has potent
vascular anti-inflammatory effects, promotes vascular recovery from injury, and increases
white blood cell count, making it an excellent candidate as a potential agent that facilitate
tissue recovery and wound repair. In a preliminary study using a dorsal window model,
C57BL/6J mice received 7-Gy total body irradiation followed by a vascular wound on 5
days post-irradiation. FITC-dextran 150-kDa was used to evaluate blood flow and vessel
perfusion, and Rhodamine-6G was used to evaluate leukocyte activity. The results, Figure
2.7, showed that injured vessels in unirradiated animals clotted immediately, had minimum
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Figure 2.7: Effect of KZ-41 on vascular injury.
KZ-41 restores microvascular flow following radiation combined injury at the vascular level.
The images shown are of a vascular wound (a nick in the vessel) in the dorsal window
of animals that received 7-Gy TBI (total body irradiation). The vascular wound was made
5 days post-TBI and 3 days post-window placement. Top and bottom rows show vessels
immediately and 24-hrs post-wound (200X) after injection of rhodamine-6G which stains
leukocytes. Note the lack of clot in the irradiated animal’s microvessel (B) and the restora-
tion of the clot in the treated animal (C). Center row: 24-hrs post-wound following injection
of FITC-dextran 150-KDa (100X). 150-kDa FITC-dextran was used to evaluate vessel per-
fusion, as the molecule is large enough that there is minimal extravasation. Note that
perfusion was restored within seconds in control animals (D), was diminished in irradiated
animals (E), and similar to control in irradiated animals treated with KZ-41 (F) (both E and
F are acquired at 3 min post-dye injection). Leukocyte activity was lacking in both TBI (H)
and TBI + KZ-41 treated (I) as compared to control (G) at 24-hrs post-wound.
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alteration in blood flow or vessel perfusion, and had a significant amount of leukocyte ac-
tivity. The restoration of the vessel was seen by 24-hrs after injury. In contrast, animals that
received total body irradiation showed no clot formation at any time, blood flow was slowed
and changing direction, minimal leukocyte activity, and by 24-hrs after injury, blood flow
was being diverted to surrounding vessels. In animals treated with KZ-41 (intraperitoneal
(100 mg/kg) daily beginning the day of irradiation) in addition to the total body irradiation,
there was an immediate clot formation, and blood flow and vessel perfusion were com-
parable to the unirradiated animals by 24-hrs after injury, however leukocyte activity was
low compared to the unirradiated group. The effects that were observed in vivo were con-
firmed using blood chemistry, Figure 2.8. with KZ-41 effectively limited leukopenia (loss
of leukocytes) at 4 days following total body irradiation. It was also observed that total
body irradiation induced a significant decrease in weight, and that treatment with KZ-41
prevented this loss, Figure 2.9.
The vascular system plays a clear role in wound healing through its delivery of oxygen,
immune cells and metabolites to the injured site and through debridement of the injured site
during the inflammation phase of healing to allow for proliferation to start. Direct damage to
the vascular bed through mechanical injury, or indirect through radiation toxicity or through
infection would interrupt these vital functions and delay wound repair. In this work, the anti-
inflammatory effects of KZ-41 are explored as a possible interventional therapy following
cranial radiation.
2.8 Gene expression
Deoxyribonucleic acid is a nucleic acid that contains the genetic instructions used in
the development and functioning of all known living organisms. DNA consists of a chain of
nucleotide subunits of four types: adenine, cytosine, guanine, and thymine. Each subunit
is made up of a phosphate group, a deoxyribose sugar ring, and a nucleobase. The way
in which the subunits are linked in the chain gives the DNA molecule a polarity with a
hydroxyl group on one end (3’ end) and a phosphate group on the other end (5’ end). A
DNA molecule is composed of two polynucleotide chains held together by hydrogen bonds.
The most common form for DNA is in a double helix structure where guanine pairs with
cytosine via three hydrogen bonds and adenine pairs with thymine via two hydrogen bonds.
The sugar-phosphates form the backbone of the double helix structure and each turn of
the helix contains 10 base pairs.
The expression of genes encoded in the DNA begins by transcribing the gene into
RNA (ribonucleic acid). RNA is similar in structure to DNA except that there is a ribose
sugar in the subunit versus deoxyribose, there are uracils instead of thymines as a nucle-
obase, and RNA is single stranded not double stranded.
During transcription, the enzyme, RNA polymerase, copies a given sequence of nu-
cleotides from DNA into a nucleotide sequence of RNA. Once the RNA sequence is made,
a type of RNA called messenger RNA (mRNA) carries the information to the ribosome of
the cell. Inside the ribosome, there is ribosomal RNA (rRNA) and transfer RNA (tRNA).
The ribosomal RNA forms the core of the ribosomes, where mRNA is translated into pro-
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Figure 2.8: KZ-41 inhibits leukopenia.
Treatment with KZ-41 maintained total white blood cell counts at 4 days post-TBI. (n ≥ 3).
• indicates a significant difference (P<0.01) compared to sham and TBI + KZ-41.
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Figure 2.9: KZ-41 prevents weight loss following total body irradiation.
Graph of animal weights following TBI. All animals (except shams) received 7Gy TBI on
Day 0. • indicates a significant difference (P<0.01) within that group compared to Day 0. 
indicates a significant difference (P<0.05) compared to TBI-only at the specified time point.
(n ≥ 4).
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tein, while transfer RNA forms adaptors that select amino acids and holds them in place
so they can be incorporated into a protein.
A cell can change the expression of its genes in response to an external signal. This
change can occur in multiple places between the DNA level and protein level. The most
common type of control is transcriptional control, where the frequency and time at which a
gene is transcribed can be controlled. Other locations for the control of gene expression
are, RNA processing and transport control, where the messenger RNA is not allowed to
carry the transcribed information to the ribosomes, translation control, where the mRNA is
not allowed to be translated into protein, or by selectively activating or inactivating proteins
after they have been made. In addition to controlling whether a gene is transcribed, the
amount of copies can be controlled.
There are a variety of ways in which gene expression can be evaluated. These in-
clude: Northern blots, Real-Time Polymerase Chain Reaction (Real-Time PCR), and mi-
croarray analysis. Northern blots use electrophoresis and a hybridization probe to mea-
sure mRNA levels. Northern blots generally provide qualitative or semiquantitative results
of mRNA levels, they require relatively large amounts of RNA, and they only detect the
expression levels for the gene specified by the probe. Real-Time PCR uses a DNA poly-
merase to amplify a piece of DNA by enzymatic replication, which is then detected via a
fluorescence marker. Real-Time PCR can provide a quantitative measurement of mRNA,
from a relatively low initial volume, however like northern blots, it is probe based, and so
only the expression levels for the gene specified by the probe can be measured. Real-
Time PCR is often used to verify the expression of a limited number of genes found to be
significant using microarray analysis.
Microarray analysis is a high-throughput technique that allows for the large-scale anal-
ysis and quantification of genes and gene expression. The microarrays consist of an
ordered arrangement of sequences (oligonucleotides, cDNA, etc) attached, via covalent
bonds, to the solid surface of a chemical matrix approximately 1.2cm x 1.2cm in size. The
protocol for the preparation of the microarrays using cDNA is as follows: 1) Isolate the RNA
from the source material (cells, tissues, etc), 2) synthesize the total RNA to cDNA, 3) use
the cDNA as a template to generate biotin-labeled in vitro transcribed cRNA, 4) fragment
the cDNA and hybridize it to a microarray, 5) wash and stain the microarray with streptavidin
phycoerythrin, and 6) analyze the microarray. Analysis is usually done using fluorescence
that is created during the probe-target hybridization, and can determine the abundance of
nucleic acid sequences in the target. Microarrays allow for tens-of-thousands of different
genes to be analyzed at once from a single sample.
In the brain, Mahmoud-Ahmed et al [127] performed a comprehensive study of radiation-
induced gene expression changes at different doses of radiation (2-, 10-, or 20-Gy) and
at different time points (0.25-, 1-, 5-, and 24-hrs) for the 20-Gy dose group. They show
that following 20-Gy, there are 78 genes that are modulated in the brain at 2 or more of
the measured time points, with the maximum number of genes modulated at 1- and 5-hrs
after radiation. In addition, they show that there are 24 biological pathways that are mod-
ulated by the 78 genes. At 5-hrs after radiation, where 2-, 10-, and 20-Gy analysis was
performed, there was a dose-dependent biological response observed. In another study,
Achanta et al used microarray analysis to measure gene expression in the hippocampus
at 24-hrs following different doses of radiation (0.3-, 3-, 10-, and 30-Gy) as a first step to
understanding radiation-induced cognitive decline. They showed a total of 1200 significant
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genes, however only 5 were observed across the different radiation doses. These 5 genes
(MT-I, MT-II, Hsp-27, GFAP, and c-Foc) were then verified using RT-PCR. By using pathway
analysis, the genes were shown to cluster around myc and tp53, genes that are known to
be important in the regulation of the cell cycle and/or apoptosis.
To date, there are no long-term microarray studies following cranial radiation. Using
radiation to the kidney or rectum, Kruse et al. evaluated radiation-induced gene expression
changes at 10 and 20 weeks following a single dose of 16 (kidney)- or 20 (rectum)-Gy
localized radiation. They reported that in the rectum there were 815 genes that were
differentially expressed (278 up-regulated and 537 down-regulated) at 10 weeks, and 115
genes differentially expressed (86 up-regulated and 29 down-regulated) at 20 weeks. In
the kidney, there were only 40 genes differentially expressed (31 up-regulated and 9 down-
regulated) at 10 weeks and 46 (42 up-regulated and 4 down-regulated) at 20 weeks. In
both the rectum and kidney, there were very few genes that were common between the
two time points, however there were genes related to vascular injury, in which they were
actually interested in.
This work uses microarray analysis to create a gene profile of the acute damage fol-
lowing radiation to gain insight into the inflammatory, vascular and parenchymal response.
The responses identified could then be explored as possible targets for interventional ther-
apy in order to abrogate the late effects observed following cranial radiation.
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Chapter 3
Materials and Methods
3.1 In vivo measurements
3.1.1 Animal model
Male C57BL/6J mice (8-10 weeks of age) were purchased from Jackson Laboratories
(Bar Harbor, ME). All protocols followed the policy guidelines of the National Institutes
of Health for the humane care and use of laboratory animals and were approved by the
Animal Care and Use Committees of St. Jude Children’s Research Hospital and The
University of Tennessee Health Science Center.
3.1.2 Cranial window
Cranial window surgery was performed according to a previously published protocol
[128]. Briefly, animals were anesthetized with an i.m. injection of ketamine/xylazine solu-
tion (100 mg/kg ketamine + 10 mg/kg xylazine), and placed in a stereotaxic frame (Kopf
Instruments, Tujunga, CA). The scalp, underlying soft tissue, skull bone and dura were
removed, and a glass cranial window (4 × 6 mm), extending from the bregma to lambdoid
sutures and centered on the midsagittal suture, was placed and fixed over the surgically
exposed cerebral cortex using cyanoacrylate glue, Figure 3.1. After surgery, animals were
allowed to recover for 7-10 days before data collection was initiated.
3.1.3 Radiation treatment
This study used a single dose of 20-Gy localized brain irradiation. The irradiator used
was a cesium irradiator, Figure 3.2, at the Veterans Affairs Medical Center in Memphis Ten-
nessee. While inside the irradiator chamber, the animals were anesthetized and secured
to a platform using Velcro. All studies were done with localized cranial irradiation using a
specially designed collimator (JL Shepard and associates, CA) allowing only a 1 cm wide
field of irradiation (i.e., a 1 cm wide strip of radiation). From previous experiments studying
localized radiation, this amount of radiation does not cause impairment to the animals. The
irradiation field was confined to the brain with adequate lead shielding to ensure that tissue
outside the field received less than 3% of the prescribed dose.
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Figure 3.1: Picture of a mouse after placement of the cranial window.
A mouse with a cranial window in place. The window provides access to the vasculature
of the pial layer of the brain. By using the intravital microscope and fluorescent dyes, we
visualized changes.
Figure 3.2: Irradiation set-up. Animals are irradiated using a cesium 137 source. There is
a specially designed lead collimator inserted into the radiation chamber that limits exposure
to a 1 cm wide strip field. Animals are placed in a specially-designed plexi-glass platform,
in a horizontal position, such that only the cerebrum of the brain is exposed. The rest of
the body is sheilded and receives less than 3% of the prescribed dose.
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3.1.4 Anti-inflammatory treatments
Animals receiving an antibody treatment were administered either purified rat anti-
mouse TNF mAb (MP6-XT3), purchased from Pharmingen (San Diego, CA, catalog
#554414) or purified rat anti-mouse ICAM-1 mAb (YN1/1.7.4) purchased from eBioscience
(San Diego, CA, catalog #16-0541). These antibodies are used to react with mouse TNF
and ICAM-1 expressed on the endothelial cell surface. Two doses of anti-TNF or anti-
ICAM-1 were given to the mice: one dose (2.0 mg/kg, i.v.) at 15 minutes before irradiation,
and another dose (2.0 mg/kg, i.v.) at 23 hours after irradiation. Purified rat IgG, purchased
from Pharmingen (San Diego, CA, catalog #554682), was used as a control for the specific
antibodies.
KZ-41 was obtained from Dr Ryan Yates and Dr Duane Miller from the pharmaceu-
tical science department at the University of Tennessee Health Science Center. Animals
receiving KZ-41 received an i.p. injection at 30 minutes prior to irradiation and at 23- and
47-hrs after irradiation. KZ-41 was administered at a dose of 100mg/kg.
3.1.5 Recombinant TNF
To confirm the role of TNF in the response to irradiation, 0.5 µg recombinant TNF
(rTNFα BD Pharmingen, San Jose, CA; cat # 554589) was administered via retro-orbital
injection in mice with cranial windows. Measurements of leukocyte adhesion and vessel
diameter were made as described above using Rhodamine-6G. Activated astrocytes were
also measured. Measurements were made before injection and at 7- and 24-hrs post-
injection of rTNF. In addition, mice treated with rTNF were analyzed for activated astrocytes
at 7- and 24-hrs post-injection or rTNF.
3.1.6 Intravital microscopy and BBB permeability
The BBB permeability and leukocyte adhesion measurements using intravital mi-
croscopy, Figure 3.3, have been described in detail previously [128, 9]. Briefly, to visualize
cerebral microcirculation, animals were anesthetized with ketamine-xylazine as described
above and placed in a stereotaxic frame under a fluorescence intravital microscope. Flu-
orescein isothiocyanate (FITC)-dextran (Sigma, St. Louis, MO) with a molecular size of
4.4-kDa was used as a permeability tracer. Before dye injection, a microvascular region
with 2-3 venules, arterioles, and clear parenchymal tissue was chosen and a reference
image (for localization of vessels) recorded under epifluorescence illumination was ac-
quired. A bolus of FITC-dextran in saline (10 mg/kg body weight) was injected through
the retro-orbital vein. The changes in intensity levels in the brain were digitally recorded
after injection every second for the first 2 minutes, then for 5 seconds every 30 seconds
for 5 minutes and then for 5 seconds every minute for up to 20 minutes. Figure 3.4 is
an example of the extravasation of the FITC-dextran over a period of 5 minutes. This
procedure was designed to minimize fluorophore excitation. All Images were made using
an industrial-scale intravital microscope, Figure 3.3, (model NM-11, Nikon USA, Melville,
NY) with a digital camera (Photometric CoolSnap ES, Roper Scientific, Trenton, NJ) and
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Figure 3.3: A picture of the intravital microscopy set-up.
The intravital microscope setup consists of an industrial scale microscope base designed to
support the weight of a stereotaxic frame, used to minimize movement by the animal. There
are long-distance working objectives that capture the fluorescent images. The working
distance of the objectives allows us to focus on the surface of the brain through the glass
window without being directly on the glass. Filter cubes control the wavelength of light that
is allowed to pass to the subject for excitation and to the CCD camera as emission. The
CCD camera is controlled by MetaMorph Imaging software which is used to capture the
digital images and perform off-line analysis.
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Figure 3.4: FITC-dextran 4.4kDa injection.
Visually, the extravasation of dye into the tissue is indicative of barrier permeability, the
more dye that accumulates in the tissue the more permeable the BBB is. This series of
images is an example of the data captured for analysis of BBB permeability to radiation.
Upper: prior to injection, Center: peak intensity after injection of 4.4 kDa FITC-dextran, and
Lower: 5 minutes post-injection. The images shown were taken at 24-hrs after irradiation
where BBB permeability known to be increased.
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bright field (175 W mercury) light source. Images were analyzed off-line using MetaMorph
software (Universal Imaging Co., West Chester, PA) to measure the extravasation rate of
FITC-dextran from vessels to tissue, which is proportional to the slope of the change of
tissue intensity versus time [128].
To calculate BBB permeability, two rectangular regions of interest (ROI) are chosen in
the vessel and in the surrounding tissue and their average intensity is recorded over time,
Figure 3.5. Our analysis method follows closely those reported by Wu et al [129], and Yuan
et al [130], with some modifications. For slow extravasation processes, Fick’s law can be
used to show that the permeability (P) and the rate of change of the tissue intensity due to
dye extravasation (dI/dt) are related [130].
P = (1− Hct ) 1Iv ∗ VS ∗ (
dIint
dt − dIsvdt )
It is the tissue intensity, Iv is the initial fluorescence intensity in the vessel, V/S is the
ratio of vessel volume and surface area, and Hct is the local hematocrit and is set at its
normal value of 32% [131, 83]. We limit our calculation of (dIint/dt− dIsv/dt) to the time period
between 30 s and 5 min after tracer injection to ensure that the dye is completely mixed.
During this period, the extravasation process was approximately linear, and back flux of the
tracer into the plasma compartment is secondary to the primary signal being measured. It
is important to note that this is a 2D analysis of a 3D process.
Previous work by Hong Yuan [132], showed that there is a linear relationship, in vitro
and in vivo, between dye concentration and emitted fluorescence intensity. This relation-
ship was maintained in the current work. In addition, the depth of field for the objective
used for in vivo measurements was calculated to be 10.4µm, with a working distance of
16.5mm at a resolution of 0.92µm. The resolution of the camera used is 1300 x 1030 with
6.7 x 6.7µm pixels.
3.1.7 Leukocyte-endothelial interactions
Leukocyte adhesion was measured by injecting Rhodamine-6G (0.4 mg/kg body
weight; Sigma, St. Louis, MO) through the retro-orbital vein to stain the leukocytes.
Rhodamine-6G is a lipophilic, positively charged fluorescent dye that selectively stains
mitochondria, and achieves a 99.99% staining of leukocytes up to 5 minutes after injec-
tion at the concentration that was used in this study [133]. A leukocyte in contact with the
vessel wall was considered to be adherent if it did not move for 30 seconds; this mea-
sure is expressed as the number of adherent cells per 100-µm length of vessel [128]. The
measurements were conducted in venules with diameters ranging from 30 to 45 µm. Per-
meability and adhesion measurements were carried out in the same vessels (n = 3-5) for
each animal at each time point, before and after irradiation.
3.1.8 Vessel diameter measurements
The diameter of the arterioles and venules were measured in all animal groups (Figure
3.6). Diameters were measured 15 seconds after the peak of the FITC-dextran injection.
This time point ensured that the dye filled the vessels so that the full diameter could be
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Figure 3.5: Permeability measurement.
When 4.4 kDa FITC-dextran is injected, a region of interest is drawn in the vessel and tis-
sue next to the vessel. Then, the average intensity of the two regions is recorded over time.
The slope of the difference between the two regions is used as the rate of extravasation for
the permeability calculation.
measured but was far enough from the peak to avoid light scatter in the measurement.
Diameter measurements were made using digital calipers that had been calibrated. The
calibration was done by determining the number of pixels on the image in a known distance
using a micrometer. A calibration was done for each objective that was used. Measure-
ments were carried out in the same vessels (n = 4-6) for each animal at each time point
before and after radiation.
3.1.9 Statistics
Statistical analyses were carried out using SigmaStat® software (version 2.03, SPSS
Science, Chicago, IL). The effects of radiation on BBB permeability and leukocyte adhe-
sion were determined by repeated analysis of variance (ANOVA), and a multiple compar-
ison procedure (Dunnett test) was used to discriminate among the means. Results of
the effects of radiation on BBB permeability and leukocyte adhesion between treatment
groups were compared using the student t-test. Data are presented as mean ± SEM, and
differences between the means were considered to be statistically significant at the prob-
ability value P<0.05. Linear regression analysis was used to investigate the correlation
between BBB permeability and leukocyte adhesion measured in vivo in the same animals.
Leukocyte adhesion was set as the dependent variable and BBB permeability as the inde-
pendent variable. The coefficient of determination, r2, was used to asses the strength of
the model as it describes the fraction of the observed variance that can be explained by
the given variables. The correlation coeficient can be obtained by taking the square root
of r2, and represents the strength and direction of the linear relationship between between
BBB permeability and leukocyte adhesion.
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Figure 3.6: Vessel diameter measurement.
Arteries are identified by their smooth surface, as compared to the venules, and at time
of injection. Dyes are injected via the retro-orbital vein, so in the vasculature measured
in the cranial window, the dye fills the arteries first (Left) and then enters the venules. At
approximately 15 seconds after the peak of the injected dye, calibrated calipers are used to
measure at multiple locations along vessels to obtain an average vessel diameter (Right).
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3.2 Histological measurements
3.2.1 Tissue collection
Anesthetized mice were perfused through the left ventricle of the heart with hep-
arinized saline (0.9%). Following perfusion, whole brain tissue was removed and sectioned
at the center in the coronal plane. The anterior portion was used for immunofluorescence
staining and was snap frozen in Tissue-Tek O.C.T. Compound (Fisher Scientific, Pittsburgh,
PA) in liquid nitrogen. The posterior portion was used for immunohistochemistry studies
and placed in 10% buffered formalin overnight prior to embedding in paraffin.
3.2.2 Immunohistological staining
Glial fibrillary acidic protein (GFAP) was used to stain for activated astrocytes. Rabbit
anti-cow GFAP (cat # N1506), and rabbit immunoglobulins (negative control, cat # X0903)
were purchased from DAKO (Carpinteria, CA). The secondary antibody for GFAP, biotiny-
lated goat anti-rabbit, were purchased from Vector (cat # BA-1000, Burlingame, CA) and
used at a 1:200 dilution. Immunohistochemistry assays were performed on the DAKO au-
tostainer at room temperature. The number of GFAP-stained astrocytes were counted in
five fields at 200x magnification in the cerebral cortex overlying the dentate gyrus of the
hippocampus, and in the hippocampus itself using a light microscope, Figure 3.7. Each
image presented is representative of n = 3 animals.
3.2.3 Immunofluorescence staining
Frozen brains will be sectioned at 7µm using a cryostat and mounted on poly-1-lyisne-
coated glass slides. Slides will be incubated with; goat anti-mouse TNF (Cat# sc-1350) or
goat anti-mouse ICAM-1 (Cat# sc-1511) antibody at a 1:100 dilution for 60min, followed
by a fluorescence-conjugated secondary antibody for 45 min. All antibodies and mounting
medium were purchased from Santa Cruz Biotechnology, Santa Cruz CA. The sections
were analyzed for protein expression at 400x magnification in the cerebral cortex overlying
the dentate gyrus of the hippocampus, and in the hippocampus itself, Figure 3.7. These
areas were chosen because they are identifiable which ensures that similar locations are
evaluated in all sections. Each image presented is representative of n = 3 animals.
3.2.4 Statistics
Statistical analyses were carried out using SigmaStat® software (version 2.03, SPSS
Science, Chicago, IL). Results of the effects of radiation on astrogliosis between treatment
groups were compared using the student t-test. Data are presented as mean ± SEM,
and differences between the means were considered to be statistically significant at the
probability value P<0.05.
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Figure 3.7: Regions used for histological analysis.
All measurements for both immunohistochemistry and immunofluorescence were made in
the cerebral cortex overlying the dentate gyrus of the hippocampus. The activated astro-
cytes were also counted in the dentate gyrus region to confirm that the changes in astro-
cyte activation in the cerebral cortex represented changes in other regions of the brain.
The black boxes represent areas that were analyzed in the cerebral cortex, and red boxes
represent area that were analyzed in the denate gyrus region.
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3.3 Microarray experiments
3.3.1 Tissue collection
Animals received a single dose of 20-Gy localized brain irradiation. Mice were sacri-
ficed at 2-hrs after a single dose of irradiation. Upon sacrifice, whole brains were removed
and snap frozen in liquid nitrogen. Brains were stored in a -80ºC freezer until analyzed.
A total of six samples were collected at each time point. The five samples with the purist
RNA were chosen to use on the microarray chips.
3.3.2 RNA preparation
For RNA extraction, frozen whole mouse brain (300 - 500 mg) tissue was added to
5 ml of STAT-60 (Tel-Test, TX), homogenized, using a Polytron homogeninizer and stored
on ice for 10 min. Chloroform/isoamyl (24:1, v:/v) ETOH was added to the homogenate
and centrifuged at 12000g for 30 min (4ºC). Following centrifugation, the aqueous phase
was transferred to a fresh tube, RNA was precipitated with isopropanol overnight at –20ºC,
pelleted by centrifugation at 12000g for 30 min (4ºC), and resuspended 100 µl of RNase-
free water. Total RNA was quantified using a NanoDrop Spectrophotometer (NanoDrop
Technologies, Rockland, DE) , and qualified by running 1 µl of each sample onto a RNA
Lab-On-A-Chip using a Agilent Bioanalyzer 2100 (Agilent technologies, Mountain View,
CA).
3.3.3 Chip preparation
Isolated total RNA samples were processed as recommended by Affymetrix (Affy-
metrix GeneChip Expression Analysis Technical Manual, Affymetrix, Inc.). Briefly, total
RNA (8 mg) was synthesized to cDNA using the Superscript Double-Stranded cDNA syn-
thesis kit (Invitrogen Corp, Carlsbad, CA) and poly dT-nucleotide primers that contain a
sequence recognized by T7 RNA polymerase. The newly synthesized cDNA was used as
a template to generate biotin-labeled invitro transcribed (IVT) cRNA using the Bio-Array
High Yield RNA transcript labeling kit (Enzo Diagnostics, Inc, Farmingdale, NY). Twenty
micrograms of the cRNA was fragmented to strands of 35 to 200 bases in length. The
fragment cRNA was hybridized to and Affymetrix MOE 430 2.0 array GeneChip at 45ºC
with rotation for 16 h (Affymetrix GeneChip Hybridization Oven 320). The GeneChip arrays
were washed and stained (streptavidin phycoerythrin) on an Affymetrix Fluidics Station
400, followed by scanning. Chips were analyzed using an Affymetrix GC 3000 System.
3.3.4 Chip analysis
The Entrez Gene ID’s of the statistically significant genes were uploaded as a list to
Webgestalt [134]. Webgestalt is a “WEB-based GEne SeT AnaLysis Toolkit” that is avail-
able for free online through Vanderbilt University (http://bioinfo.vanderbilt.edu/webgestalt/).
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One of the many functions of Webgestalt is gene set organization and visualization that
includes: KEGG Tables and Maps, GOTree’s, Tissue Expression Bar Charts, BioCarta Ta-
ble and Maps, and Protein Domain Tables. For the current study, KEGG Tables and Maps
were utilized in order to organize the data. The KEGG Table organizes the genes from the
given list based on the known KEGG biochemical pathways. The KEGG Table provides the
KEGG pathways associated with the gene set, the total number of genes in each pathway
present in the given gene set, and the Entrez Gene IDs for the genes in the set. Once We-
bgestalt generated the KEGG Table, the pathways present in the table were then manually
grouped by molecular interaction and reaction networks.
3.3.5 Statistics
Data output from MAS 5.0 (Affymetrix) was analyzed using GeneSpring7.3.1 (Agilent
Technologies). A parametric student t-test was used to identify the genes that were sig-
nificantly differentially expressed. In order to reduce the variations in sample loading and
staining, expression values for each probe set were normalized to the median expression
value (50th percentile) for all probe sets in each chip. When doing PCA or making his-
togram boxplot graphs, each gene was normalized to the median expression value across
the set of microarrays that were analyzed.
Before any analysis was performed, the data were filtered by flags (absent(A), pre-
sent(P) or marginal(M) detection calls) and expression values. The genes were kept if their
flag values were present or marginal and the expression values above 40 of the raw level
in at least 3 out of 5 samples.
The average of all five microarray chips for each time point were used to determine
statistical analysis and for pathway analysis. The differences between the means were
considered to be statistically significant at the probability value P<0.05.
3.4 Serum cytokines
Serum cytokine measurements were made in mice following cranial irradiation. Mice
were irradiated using the procedure above, and sacrificed at 24-, 48-, 72-hrs and 8- and
15-days post-RT. Mice were anesthetized with isoflurane, followed by a cardiac puncture
to obtain a blood sample. Approximately 0.5 to 0.8 mls of blood was collected. The sample
was allowed to coagulate for 10 minutes at room temperature before being placed on ice
for up to 30 minutes. The sample was then centrifuged for 2 x 10 minutes. The serum
was then removed and stored in microtubes at -80ºC until analysis. Analysis was done us-
ing a FlowMetrixTM system (Luminex, Austin, TX) run by the Mouse Immunophenotyping
and Cytokine Assay Lab in the Immunology department at St. Jude Children’s Research
Hospital. The cytokines that were analyzed are TNF, VEGF, IL-6, IL-10, and GCSF. The
statistical analysis of the serum cytokines was done using a mixed model method.
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Chapter 4
Mechanism of Radiation-Induced Inflammation
It is accepted that patients who receive cranial irradiation for treatment of a brain tu-
mor will incurr some side effects of treatment. These side effects generally do not appear
until months to years following treatment. However, in the field of radiation research, the
cause for these side effects is often debated. Currently, it is not accepted that: there is
a relation between acute damage and late-term damage, the importance of the vascula-
ture in radiation damage (early or late-term), and that radiation induces inflammation in
the brain. The current work aims o show that radiation induces damage to the vasculature
and parenchyma and that his damage is due to the inflammatory response that is initiated
following radiation.
Hypothesis: Brain irradiation causes an acute response which if unchecked creates
a chronic inflammatory microenvironment which amplifies radiation sequela. Treatment
with anti-TNF or anti-ICAM-1 agents during the early phase arrests this inflammatory re-
sponse and reduces radiation toxicity of the normal brain tissue.
Specific Aim: Characterize the acute damage to the blood-brain barrier, following a
single dose of 20-Gy localized cranial irradiation (RT) using a mouse cranial window model
and histological methods and evaluate the effect of treatment with anti-TNF or anti-ICAM-1
in conjunction with irradiation to abrogate inflammation-induced radiation damage.
The specific questions being investigated are:
• What is the role of TNF and ICAM-1 in the acute changes observed following radia-
tion?
• Does inhibiting TNF affect the levels of ICAM-1 and vise versa?
• Is there a correlation between the increase in vascular permeability and leukocyte
adhesion? Does blocking either molecule, TNF or ICAM-1, disrupt this correlation?
4.1 Radiation-induced changes in the permeability of the BBB
Changes in BBB permeability to 4.4-kDa FITC-dextran were measured before and at
24- and 48-hrs post-radiation (Figure 4.1). Prior to radiation, BBB permeability was 13.14
± 1.99 × 10−7 cm/s. At 24- and 48-hrs post-irradiation permeability significantly increased
to 20.30 ± 2.36 × 10−7 cm/s (P<0.05) and 21.53 ± 3.61 × 10−7 cm/s (P<0.05), respectively.
When treated with radiation and anti-TNF, BBB permeability was significantly lower at 24-
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Figure 4.1: Vascular permeability of the BBB following irradiation.
Radiation induces an increase in vascular permeability of the BBB at 24- and 48-hrs fol-
lowing 20-Gy localized cranial irradiation. When the inflammatory response is limited via
treatment with either TNF or ICAM-1 antibody, the increase in vascular permeability is
inhibited. # P<0.05 versus Control, * P<0.05 versus RT-only at the given time point.
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and 48-hrs compared to the radiation-only group. The respective values were 14.73 ± 1.12
× 10−7 cm/s (P<0.05) and 15.14 ± 1.17 × 10−7 cm/s (P<0.05). Similarly, when treated with
radiation and anti-ICAM-1 BBB permeability was significantly lower, 14.42 ± 0.77 × 10−7
cm/s (P<0.05) and 15.33 ± 1.18 × 10−7 cm/s (P<0.05) at 24- and 48-hrs post-irradiation,
respectively. In the sham group (RT + IgG administered), permeability was not significantly
different that RT-only at any time point (14.27 ± 0.97 × 10−7 cm/s, 22.63 ± 2.32 × 10−7
cm/s, 21.32 ± 2.03 × 10−7 cm/s, at control, 24- and 48-hrs respectively).
4.2 Radiation-induced leukocyte adhesion in the brain
Radiation induced a significant increase in leukocyte adhesion in venules (Figures 4.2
and 4.3). Prior to radiation, leukocyte adhesion was 0.45 ± 0.13 adhering leukocytes/100 µm
and was significantly increased compared to control at 24- and 48-hrs post-radiation: 1.01
± 0.25 (P<0.05) and 1.02 ± 0.15 (P<0.01), adhering leukocytes/100 µm, respectively.
When treated with radiation and anti-TNF, adhesion was significantly lower up to 48 hrs
post-radiation. Adhesion was 0.49 ± 0.12 (P<0.05) and 0.44 ± 0.12 (P<0.01), adhering
leukocytes/100 µm, at 24- and 48-hrs post-radiation, respectively. Similarly, when treated
with radiation and anti-ICAM-1 the number of adhering leukocytes was significantly less at
24- (0.46 ± 0.17 adhering leukocytes/100 µm; P<0.05) and 48-hrs (0.52 ± 0.19 adhering
leukocytes/100 µm; P<0.05) compared to radiation-only. Treatment with radiation and IgG
did not cause the number of adhering leukocytes to differ from radiation alone at any time
point. There was no adhesion observed in arterioles in any group at any time point.
4.3 Changes in pial vessel diameters following cranial irradiation
In the radiation-only group, there was a significant decrease in arteriole diameter at
48-hrs post-irradiation (22.45 ± 1.16 µm; P<0.05), compared to before radiation (27.16 ±
2.17 µm), Figure 4.4. When treated with radiation and anti-TNF there was no decrease
in arteriole diameter, making the average arteriole diameter significantly larger at 48-hrs
(29.10 ± 1.43 µm; P<0.01) post-irradiation in the radiation and anti-TNF treated group
than in the radiation-only group (22.45 ± 1.16 µm). Similarly, treatment with radiation and
anti-ICAM-1 inhibited the loss in arteriole diameter at 48-hrs post-irradiation. The average
arteriole diameter at 48-hrs in the radiation and ICAM-1 group was (28.63 ± 2.40 µm;
P<0.05). Animals treated with radiation and IgG exhibited the same decrease in arteriole
diameter at 48-hrs post-irradiation (28.29 ± 1.12 µm; P<0.05) as the radiation-only group.
There was no significant change in the diameter of the venules in the radiation-only or in
any treated group at any time point measured.
4.4 Correlation between BBB permeability and leukocyte adhesion
Leukocyte adhesion has been implicated in endothelial cell remodeling which, in turn,
could lead to changes in vascular pore size and increases in permeability [114, 128]. To
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Figure 4.2: Leukocyte adhesion following irradiation.
Radiation induces an increase in adhering leukocytes in the pial vessels of the brain at 24-
and 48-hrs following 20-Gy localized cranial irradiation. When the inflammatory response
is limited via treatment with either TNF or ICAM-1 antibody, the increase in adhering leuko-
cytes is inhibited. # P<0.05, ## P< 0.01 versus control, * P<0.05 versus RT-only at the
given time point.
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Figure 4.3: Representative images of radiation-induced leukocyte adhesion.
Representative images of the changes observed in leukocyte adhesion 24-hrs following
RT. (A-C) Control images with few adherent leukocytes observed (D) 24-hrs post-20-Gy
RT-only; a significant amount of adhering leukocytes are visible. (E) 24-hrs post-20-Gy
RT+ anti-TNF and (F) 24-hrs post-20-Gy RT + ICAM-1; when treated prior to irradiation,
the adhering of leukocytes can be inhibited. Images were taken at approximately the same
time after injection of Rhodamine-6G.
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Figure 4.4: Radiation-induced changes in vessel diameter.
Radiation induces a decrease in arteriole vessel diameter at 48-hrs following a single dose
of 20-Gy localized cranial radiation. This decrease in vessel diameter is inhibited when the
inflammatory response is limited. There is a significant difference between both treated
groups and radiation-only at 48-hrs post-radiation. # P<0.05 versus Control, * P<0.05 and
** P<0.01 versus RT-only at the given time point.
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investigate this possible correlation a linear regression analysis was performed with leuko-
cyte adhesion as the dependent variable. The analysis was performed using four sets of
data: radiation-only, radiation-only and radiation and anti-TNF, radiation-only and radiation
and anti-ICAM-1, and all three groups together, Figure 4.5. The results showed that the
number of adhering leukocytes significantly influences BBB permeability in each data set
analyzed. In the radiation-only group, there was a coefficient of determination of 0.8746
(P<0.001) and an increase in BBB permeability of 6.5021× 10−7 cm/s for every adhering
leukocyte in 100 µm distance. Radiation-only and radiation and anti-TNF showed a coef-
ficient of determination of 0.6499 (P<0.001) while radiation and radiation and anti-ICAM-1
showed a coefficient of determination of 0.6997 (P<0.001). When all three sets of data
were combined, the coefficient of determination was 0.6365 with an increase in BBB per-
meability of 3.77 × 10−7 cm/s for every adhering leukocyte in 100 µm distance.
4.5 Immunohistochemistry
There was a significant increase in the number of GFAP positive astrocytes in the
cerebral cortex at 24- and 48-hrs post-radiation. In the unirradiated brain there were 11.41
± 1.21 activated astrocytes/mm2, Figures 4.6 and 4.7. At 24- and 48-hrs post-irradiation ac-
tivated astrocyte counts were 21.92 ± 0.24 (P<0.001) and 22.92 ± 0.36 (P<0.001) activated
astrocytes/mm2, respectively. In the radiation and anti-TNF treated group the number of
activated astrocytes was not significantly different than control at any time point measured.
In the radiation and anti-ICAM-1 treated group, the number of activated astrocytes was
significantly greater that in the unirradiated or radiation and anti-TNF treated groups, how-
ever it was still significantly less than in the radiation-only group. At 24- and 48-hrs post-
irradiation, the activated astrocyte counts, in the radiation and anti-ICAM-1 treated group,
were 13.56 ± 0.69 activated astrocytes/mm2 and 13.38 ± 0.33 activated astrocytes/mm2,
respectively.
To confirm that the observed increase, or inhibition, of activated astrocytes in the cere-
bral cortex is consistent in other regions of the brain, activated astrocytes were counted
in the dentate gyrus region of the hippocampus. The astrocytic response in the dentate
gyrus region mimicked the response in the cerebral cortex, Figure 4.8 . The only difference
was in the number of activated astrocytes. In the cerebral cortex, the activated astrocyte
counts ranged from 11.41 ± 1.21 activated astrocytes/mm2in the unirradiated to 34.38
± 0.41 activated astrocytes/mm2, while in the dentate gyrus region, the activated astro-
cyte counts ranged from 27.57 ± 1.83 activated astrocytes/mm2 to 66.26 ± 2.05 activated
astrocytes/mm2.
In the cerebral cortex, astrocyte activation was significantly increased in the radiation
and IgG group compared to the unirradiated group at 24- and 48-hrs post-irradiation, and
not significantly different from RT-only, 27.58 ± 0.2 activated astrocytes/mm2 and 26.03
± 1.11 activated astrocytes/mm2, respectively. Similarly, in the dentate gyrus region of
the hippocampus, the number of activated astrocytes in the radiation and IgG group was
not different than the radiation-only group at 24- and 48-hrs post-irradiation (65.39 ± 1.46
activated astrocytes/mm2 and 66.56 ± 1.88 activated astrocytes/mm2, respectively).
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Figure 4.5: Correlation between BBB permeability and leukocyte adhesion.
Using linear regression analysis, we can see that there is a good correlation between
permeability of the BBB and leukocyte adhesion.
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Figure 4.5: (continued).
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Figure 4.6: Activated astrocyte counts in the cerebral cortex.
Following RT, a significant amount of astrogliosis was observed at 24- and 48-hrs and was
significantly inhibited when treated with anti-TNF or anti-ICAM-1. Treatment with radia-
tion and IgG did not effect activated astrocyte levels when compared to radiation only. *
(P<0.05) and *** (P<0.001) indicate a significant difference versus control. ### (P<0.001)
indicates a significant difference between the radiation and anti-TNF or radiation and anti-
ICAM-1 treated group and the RT-only group at that time point. † (P<0.05) indicates a
significant difference between the radiation and anti-TNF treated group and the radiation
and anti-ICAM-1 treated group at that time-point. §§§ (P<0.001) indicates a significant
difference versus radiation and IgG treatment at that time point.
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Figure 4.7: GFAP staining for activated astrocytes.
Representative images of GFAP staining at 24-hrs post-radiation (24-hrs post-injection for the recombinant TNF). There is a significant
difference in activated astrocytes in the RT-only brain, RT + IgG and the rTNF brain compared to the unirradiated and the RT + TNF
mAb, and RT + ICAM-1 mAb treated brains. Images were taken at the same exposure settings and scaled the same. Magnification
200x. Each image presented is representative of n = 3 animals. Scale bar = 100 µm
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Figure 4.8: Activated astrocyte counts in the dentate gyrus region.
To confirm that the response of the asrocytes following radiation was not limited to the
cerebral cortex, counts of astrocyte activation were also made in the dentae gyrus region
of the hippocampus. The overall response was consistent with the cerebral cortex, however
the overal counts were higher. * (P<0.05) and *** (P<0.001) indicate a significant difference
versus control. ### (P<0.001) indicates a significant difference between the radiation and
anti-TNF or radiation and anti-ICAM-1 treated group and the RT-only group at that time
point. † (P<0.05) and †† (P<0.01) indicate a significant difference between the radiation
and anti-TNF treated group and the radiation and anti-ICAM-1 treated group at that time-
point. §§§ (P<0.001) indicates a significant difference versus radiation and IgG treatment
at that time point.
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4.6 Immunofluorescence
Immunofluorescence showed an increase in protein expression of TNF and ICAM-1
at 24-and 48-hrs post-radiation in the radiation-only group, Figure 4.9. There is specific
staining of TNF and ICAM-1 localized around vessels structures, while there is no staining
observed in the unirradiated brain. There is no expression of TNF and minimal expression
of ICAM-1 observed in the animals irradiated and treated with anti-TNF. In animals treated
with radiation and anti-ICAM-1 there is no expression of ICAM-1 and minimal expression
of TNF. Observations were made in images at the same imaging settings.
4.7 Effect of TNF on cerebral vasculature
When recombinant TNF (rTNF) was administered to evaluate the role of TNF in
radiation-induced adhesion and arteriole diameter changes, a significant decrease in ar-
teriole diameter was observed. At control, the average arteriole diameter was 35.28 ±
2.12 µm, and at 7-hrs post-rTNF injection, the average arteriole diameter had significantly
decreased to 30.27 ± 2.55 µm (P<0.05), Figure 4.10. By 24-hrs post-rTNF injection, the
arteriole diameter was 31.34 ± 2.94 µm (P>0.05).
The administration of rTNF also caused a significant increase in leukocyte adhesion
in the venules and arterioles at 7- and 24-hrs post-injection, Figure 4.11. In the arterioles
there was a 92% increase at 7-hrs (P<0.001) and a 33% increase (P<0.01) at 24-hrs post-
injection. In the venules there was a 750% increase (P<0.01) at 7-hrs and a 148% increase
(P<0.01) at 24-hrs post-injection.
When rTNF was administered and immunohistochemical staining for GFAP was per-
formed, a significant amount of activated astrocytes were observed compared to the unir-
radiated, Figure 4.12. The activated astrocyte count at 7-hrs was 23.42 ± 0.21 activated
astrocytes/mm2, which is significantly different than the unirradiated. At 24-hrs the acti-
vated astrocyte count was 26.57 ± 0.29 activated astrocytes/mm2, which is significantly
higher than the unirradiated and not significantly different than the radiation-only group
4.8 Discussion
The goal of this work was to characterize the acute effects of radiation on the brain in
a mouse model, and to identify a mechanism of damage. The specific questions that were
investigated are:
• What is the role of TNF and ICAM-1 in the acute changes observed following radia-
tion?
Radiation was shown to induce changes in permeability of the BBB, leukocyte ad-
hesion in pial venules, and arteriole diameter at 24- and 48-hrs following localized
cranial irradiation. It was shown that when TNF or ICAM-1 were inhibited, via spe-
cific antibodies, these vascular changes were inhibited. In addition, radiation-induced
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Figure 4.9: Immunofluorescence staining.
Representative images of the protein expression of TNF and ICAM-1 at 24-hrs post-RT.
(A-B) unirradiated, (C-D) irradiated only, (E-F) radiation and anti-TNF treatment, (G-H)
radiation and anti-ICAM-1 treatment. (I-J) Show TNF and ICAM-1 protein expression fol-
lowing the administration of 0.5µg recombinant TNF. Magnification 400x. Images were
taken by first focusing on a DAPI image to ensure that the field was in focus. Each image
presented is representative of n = 3 animals. Scale bar = 50 µm.
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Figure 4.9: (continued).
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Figure 4.10: TNF induces changes in vessel diameter.
When rTNF is administered there is an observable decrease in arteriole diameter at 7-hrs
post-injection. This indicates that the TNF pathway may be the reason for the RT-induced
vessel diameter changes, as no changes are seen when the pathway is inhibited.
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Figure 4.11: TNF induces leukocyte adhesion.
When rTNF is administered there is an observable increase in leukocyte adhesion in both
the arterioles and venules at 7- and 24-hrs post-injection of recombinant TNF. This in-
dicates that the TNF pathway is at least partly responsible for the RT-induced changes
in leukocyte adhesion, as rTNF induces leukocyte adhesion and no change in leukocyte
adhesion is observed when the pathway is inhibited.
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Figure 4.12: TNF induces astrogliosis.
The administration of recombinant TNF induced a significant increase in activated astro-
cytes at 7- and 24-hrs post-injection. There is also a significant difference between the
number of activated astrocytes between 7-hrs post-injection and 24-hrs post-injection. At
24-hrs post-rTNF injection, the number of activated astrocytes is not significantly different
than RT-only, see Figure 4.6.
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astrocyte activation was evaluated, and it was shown that the inhibition of TNF pre-
vented astrocyte activation, while the inhibition of ICAM-1 only significantly reduced
the activation. This shows that the inflammatory molecules TNF and ICAM-1 are in-
volved in the acute radiation-induced vascular changes in the brain.
• Does inhibiting TNF affect the levels of ICAM-1 and vise versa?
Immunofluorescece staining showed that radiation induces the up-regulation on TNF
and ICAM-1 protein expression at 24- and 48-hrs post-irradiation. When antibodies
to TNF were administered in conjunction with radiation, the protein expression of both
TNF and ICAM-1 were inhibited. When antibodies to ICAM-1 were administered in
conjunction with radiation, the protein expression of ICAM-1 was inhibited, but the
protein expression of TNF was similar to the irradiated-only animal. This shows that
the antibodies used were specific to their respective molecules, and that the inhibi-
tion of TNF is more potent than he inhibition of ICAM-1.
• Is there a correlation between the increase in vascular permeability and leukocyte
adhesion? Does blocking either molecule, TNF or ICAM-1, disrupt this correlation?
Using a linear regression model, it was shown that there is a strong correlation be-
tween the increase in permeability of the BBB and the increase in leukocyte adhesion
following irradiation. This is the first time that the correlation between our two main
in vivo measurements has been determined.
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Chapter 5
KZ-41: An Interventional Therapy
KZ-41 is a potent analog of quinic acid, which is an active ingredient in hot water
extracts of the herbal cat’s claw (uncaria tomentosa). Studies have shown that the anti-
inflammatory activity of cat’s claw extracts is through the inhibition of NF-κB, and that this
inhibition is coming from the quinic acid carboxyl alkyl ester found in the extract [118].
Aqueous extracts from the bark or root bark are used therapeutically in a diversity of dis-
eases including allergy, arthritis, chemotherapy side effects, cancer, bacterial/fungal in-
fections, gastrointestinal inflammation and gastric ulcers [119, 120, 121, 122, 123]. Oral
administration of C-Med-100® to humans at doses of 250-750 mg daily has been shown
to enhance immune cell response and DNA repair [124, 125, 126]. In addition, preliminary
studies from our group indicate that KZ-41 has potent vascular anti-inflammatory effects,
promotes vascular recovery from injury, and increases white blood cell count, making it an
excellent candidate as a potential agent that facilitates tissue recovery and wound repair.
In this work, the anti-inflammatory effects of KZ-41 are explored as a possible inter-
ventional therapy following cranial radiation.
Hypothesis: KZ-41, a derivative of quinic acid that shows anti-inflammatory effects
through the NF-κB/ICAM-1 pathway, can be used to inhibit the inflammation-mediated
acute radiation effects.
Specific Aim: Evaluate the effectiveness of KZ-41 as an interventional therapy for
acute radiation damage to the blood-brain barrier following a single dose of 20-Gy local-
ized cranial irradiation and compare to the response observed from the direct inhibition of
the inflammatory molecules TNF and ICAM-1 via antibodies.
The specific questions being investigated are:
• Is KZ-41 able to inhibit the radiation-induced vascular changes known to be effected
by TNF and ICAM-1?
• Does KZ-41 affect the levels of TNF or ICAM-1 following localized cranial radiation?
• If KZ-41 works through the ICAM-1 pathway only, does it decouple the vascular re-
sponse from the astrocytic response?
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5.1 Effect of KZ-41 on radiation-induced changes to the microvasculature
It has been shown in the previous section that there are significant changes in per-
meability of the BBB to 4.4-kDa FITC-dextran, leukocyte adhesion, and arteriole diameter
changes at 24- and 48-hrs after radiation. It was also shown that directly inhibiting the
inflammatory molecules TNF or ICAM-1 would inhibit these changes. KZ-41 is thought
to work through the NF-κB/ICAM-1 pathway, and as such should have similar effects as
inhibiting these two molecules.
KZ-41 inhibits radiation-induced increases in the permeability of the BBB. Changes
in BBB permeability were measured before and at 24- and 48-hrs post-radiation Prior to
radiation, BBB permeability was 13.14 ± 1.99 × 10−7 cm/s. At 24- and 48-hrs post-radiation
permeability significantly increased to 20.30 ± 2.36 × 10−7 cm/s (P<0.05) and 21.53 ±
3.61 × 10−7 cm/s (P<0.05), respectively. When treated with radiation and KZ-41, BBB
permeability was significantly lower compared to radiation-only. At 24- and 48-hrs post-
radiation the respective values were 14.56 ± 0.36 × 10−7 cm/s (P<0.05) and 14.67 ± 0.66
× 10−7 cm/s (P<0.05). (Figure 5.1).
Leukocyte adhesion in pial venules was significantly lower in animals treated with ra-
diation and KZ-41 versus radiation alone. Prior to radiation, leukocyte adhesion was 0.45
± 0.13 adhering leukocytes/100 µm and was significantly increased compared to control
at 24- and 48-hrs post-radiation: 1.01 ± 0.25 (P<0.05) and 1.02 ± 0.15 (P<0.01), adher-
ing leukocytes/100 µm, respectively. In animals treated with radiation and KZ-41, there
was significantly less adhering leukocytes at 24- (0.5 ± 0.05 adhering leukocytes/100 µm;
P<0.05) and 48-(0.55 ± 0.15 adhering leukocytes/100 µm; P<0.05) hrs post-radiation com-
pared to radiation-only. There was no adhesion observed in the arterioles. (Figures 5.2
and 5.3).
The presence of inflammation appears to create a period of vasoconstriction in the
arterioles following radiation. Treatment with KZ-41 inhibited the radiation-induced inflam-
matory response effectively enough to inhibit this vasoconstriction. In the radiation-only
group, there was a significant decrease in arteriole diameter at 48-hrs post-radiation (22.45
± 1.16 µm), compared to before radiation (27.16 ± 2.17 µm), Figure 5.4. When treated with
radiation and KZ-41 there was no decrease in arteriole diameter observed, making the
average arteriole diameter significantly larger at 48-hrs (30.33 ± 1.16 µm; P<0.01) post-
radiation in the radiation and KZ-41 treated group than in the radiation-only group (22.45 ±
1.16 µm). There was no significant change in the diameter of the venules observed.
5.2 Effect of KZ-41 on the radiation-induced astrocytic response
Activated astrocytes are known to be a sign of injury in the brain. In addition as-
trocytes are known to secrete the inflammatory molecules TNF and ICAM-1. Therefore
the relationship between the inflammation affecting the vasculature and the astrocytic re-
sponse is of great interest. In the previous section it was shown that radiation induces the
activation of astrocytes and that be inhibiting TNF or ICAM-1 astrocytic acivation can be
significantly lowered or inhibited. In the unirradiated brain there were 11.41 ± 1.21 activated
astrocytes/mm2, Figures 5.5 and 5.6. At 24- and 48-hrs post-radiation activated astrocyte
59
00.2
0.4
0.6
0.8
1
1.2
1.4
Control 24 48
Time post-RT (hours)
#
 o
f  
A
d
h
e
r i
n
g
 l
e
u
k
o
c
y
t e
s
 /
1
0
0
!
m
RT-only
RT + KZ-41
  #
  #
*
*
Figure 5.1: Vascular permeability of the BBB following radiotherapy following KZ-41.
Radiation induces an increase in vascular permeability of the BBB at 24- and 48-hrs fol-
lowing 20-Gy localized cranial irradiation. When the inflammatory response is limited via
treatment with KZ-41, the increase in vascular permeability is inhibited.
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Figure 5.2: Leukocyte adhesion following radiotherapy can be inhibited by KZ-41.
Radiation induces an increase in adhering leukocytes in the pial vessels of the brain at 24-
and 48-hrs following 20-Gy localized cranial irradiation. When the inflammatory response
is limited via treatment with an antibody (anti-TNF or anti-ICAM) or with KZ-41, the increase
in adhering leukocytes is inhibited.
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Figure 5.3: Representative images of radiation-induced leukocyte adhesion.
Representative images of the changes observed in leukocyte adhesion 24-hrs following
RT. (A-D) Control images with few adherent leukocytes observed (E) 24hrs post-20Gy RT-
only; a significant amount of adhering leukocytes are visible. (F-H) 24hrs post-20Gy RT+
anti-TNF, RT + ICAM-1, and RT + KZ-41; when treated prior to radiation, the adhering
of leukocytes can be inhibited. Images were taken at approximately the same time after
injection of Rhodamine-6G.
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Figure 5.4: Radiation-induced changes in vessel diameter.
Radiation induced a decrease in arteriole vessel diameter at 48-hrs following a single dose
of 20-Gy localized cranial radiation. This decrease in vessel diameter is inhibited when the
inflammatory response is limited via treatment with KZ-41.
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Figure 5.5: Activated astrocyte counts in the cerebral cortex is exacerbated with KZ-
41.
Following radiation, a significant amount of astrogliosis was observed at 24- and 48-hrs
and was significantly inhibited when treated with anti-TNF or anti-ICAM-1. However, KZ-41
induced astrogliosis to levels significantly higher than RT-only. ### (P<0.001) indicates a
significant difference versus control. $$$ (P<0.001) indicates a significant difference versus
radiation and KZ-41 treatment at that time point.
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Figure 5.6: GFAP staining for activated astrocytes.
Representative images of GFAP staining at 24-hrs post-radiation with and without treatment with KZ-41. There is a significant difference
in activated astrocytes in the radiation and KZ-41 treated group versus the unirradiated and a significant difference between RT-only
and radiation and KZ-41. Images were taken at the same exposure settings and scaled the same. Magnification 200x. Each image
presented is representative of n = 3 animals. Scale bar = 100 µm.
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counts were 21.92 ± 0.24 (P<0.001) and 22.92 ± 0.36 (P<0.001) activated astrocytes/mm2,
respectively. In animals treated with radiation and KZ-41, the number of activated as-
trocytes was significantly greater than both the unirradiated group and the radiation-only
group. At 24- and 48-hrs post-radiation, the activated astrocytes counts were 33.69 ± 0.55
activated astrocytes/mm2 and 34.38 ± 0.41 activated astrocytes/mm2, respectively.
To confirm that the observed increase of activated astrocytes in the cerebral cortex is
consistent in other regions of the brain, activated astrocytes were counted in the dentate
gyrus region of the hippocampus. In the unirradiated and radiation-only groups, the astro-
cytic response in the dentate gyrus region mimicked the response in the cerebral cortex.
In the radiation and KZ-41 treated group, however, the significant increase in activated as-
trocytes over the radiation-only group is lost. There are still significantly more astrocytes in
the radiation and KZ-41 group than in the unirradiated brain, but it is no longer significantly
different than the radiation-only group, Figure 5.7 .
5.3 Inhibition of protein expression using KZ-41
Immunofluorescence staining can be used to visualize protein expression. In the pre-
vious section, it was shown that in the unirradiated brain there is virtually no expression
of TNF or ICAM-1 at the protein level, while there is expression in the irradiated brain at
24-hrs post-irradiation. When TNF antibody was administered in conjunction with radia-
tion, immunofluorescence staining showed that both TNF and ICAM-1 protein expression
was inhibited. As expected, when ICAM-1 antibody was administered in conjunction with
radiation, ICAM-1 expression was inhibited, but TNF expression was not different than
irradiated-only, Figure 5.8. Similarly in the radiation and KZ-41 treated animals, there is
minimal expression of ICAM-1 while TNF expression is most similar to the irradiated-only
group. This staining pattern is not unexpected as KZ-41 is thought to work through the
NF-κB/ICAM-1 pathway, and not directly inhibit TNF. Observations were made in images
at the same imaging settings.
5.4 Discussion
The goal of this work was to evaluate the effectiveness of the novel anti-inflammatory
agent KZ-41 to limit the inflammatory-mediated radiation response in the brain. The spe-
cific questions investigated were:
• Is KZ-41 able to inhibit the radiation-induced vascular changes known to be effected
by TNF and ICAM-1?
When KZ-41 was administered in conjunction with radiation, it was able to abrogate
the radiation-induced changes to the vasculature. It inhibited: permeability increases
in the BBB, leukocyte adhesion in the pial venules, and prevented the vasoconstric-
tion of the arterioles at 48-hrs post-irradiation.
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Figure 5.7: Activated astrocyte counts in the dentate gyrus region following radia-
tion and KZ-41.
To confirm that the response of the asrocytes following radiation was not limited to the cere-
bral cortex, counts of astrocyte activation were also made in the dentate gyrus region of
the hippocampus. The overall response was consistent with the cerebral cortex, however
the overal counts were higher. However, the significant difference between the number of
activated astrocytes in the radiation-only and radiation and KZ-41 treated group was not
observed. ### (P<0.001) indicates a significant difference versus the unirradiated group.
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Figure 5.8: Protein inhibition via KZ-41 administration.
Representative images of the protein expression of TNF and ICAM-1 at 24-hrs post-RT.
(A-B) unirradiated, (C-D) irradiated only, (E-F) radiation and KZ-41, Z-41. Magnification
400x. Images were taken by first focusing on a DAPI image to ensure that the field was in
focus. Each image presented is representative of n = 3 animals. Scale bar = 50 µm
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• Does KZ-41 affect the levels of TNF or ICAM-1 following localized cranial radiation?
It is thought that the anti-inflammatory properties of KZ-41, a derivative of quinic
acid, are through the inhibition of NF-κB. When KZ-41 was administered in con-
junction with cranial irradiation, ICAM-1 protein expression was inhibited while TNF
protein expression was not different than irradiation-only. The observed inhibition of
ICAM-1 does support the hypothesis that KZ-41 work through the inhibition of NF-κB.
• If KZ-41 works through the ICAM-1 pathway only, does it decouple the vascular re-
sponse from the astrocytic response?
When KZ-41 was administered in conjunction with radiation, there was an inhibition
in the vascular response that was observed at 24- and 48-hrs post-irradiation. How-
ever, when activated astrocytes were counted, the inhibition of the vascular changes
did not prevent the astrocytic response. In fact, the addition of KZ-41 exacerbaed
the astrocyte activation, significantly increasing it compared to radiation alone. This
differs from the response seen when specific antibodies were used against the in-
flammatory molecules TNF and ICAM. When antibodies were administered, both the
vascular and astrocytic responses were inhibited.
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Chapter 6
Early Markers of Radiation-Induced Damage
Genes are the genetic instructions used in the development and function of all known
living organisms. Identifying and understanding genes is the key to understanding how
many diseases affect the body, and how to effectively treat these diseases. In October
1990, a 13-year international effort was initiated to sequence the complete human genome.
This was known as the Human Genome Project (HGP). With the HGP, 20,000 to 25,000
genes were identified, with approximately 3 million base pairs. Work continues today un-
derstanding how genes and gene expression is altered during different disease states.
Figure 6.1 shows a schematic representation of the series of acute response events
that occur following localized whole brain radiation. There are three main types of re-
sponse: protein, serum cytokine, and gene expression. The protein response has been
characterized in the previous chapter and includes: increased expression of ICAM-1 and
increased cell adhesion and infiltration leading to damage of the microvascular network.
Serum cytokines are proteins secreted by various cells, which regulate immunity, inflam-
mation, and hematopoiesis, measured in serum rather than in whole blood. Cytokines act
by binding to specific receptors, which then trigger a cell to alter its behavior. The third
type of response is from changes in gene expression. This work begins to understand
the changes in the gene profile of the irradiated brain in an attempt to better understand
radiation damage.
Hypothesis: The gene profile of the acute damage following radiation can give an
insight into the inflammatory, vascular, and parenchymal pathways that could be targeted
for interventional therapy to abrogate radiation-induced late effects.
Specific Aim: Investigate the acute inflammatory, vascular, parenchymal, and neu-
rostructural changes in the brain following radiation damage by characterizing the gene
response using microarray gene expression analysis.
The specific questions being investigated are:
• Is there a paracrine response that occurs?
• Can we distinguish between parenchymal and vascular damage?
• Are there early signs of neurostructural damage?
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Figure 6.1: Schematic of the acute molecular responses following radiation.
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6.1 Microarray analysis
The changes in gene expression following a single dose of 20-Gy radiation localized
to the brain, were evaluated to extend our in vivo analysis to the most basic level of change.
At 2-hrs following a single dose of 20-Gy localized cranial irradiation there were 2514 genes
significantly different versus control at P<0.05, and 656 genes significantly different than
control at P<0.01, Table 6.1. Of the 2514 genes significantly different at the P<0.05 level,
64 showed a fold change of 2 or greater (26 genes up-regulated and 38 genes down-
regulated). In addition, 409 genes showed a fold change of 1.5 or greater with 141 genes
up-regulated and 268 genes down-regulated. The time point of 2-hrs post-irradiation was
chosen because previous work by Sabek et al. showed that radiation-induced changes in
TNF and ICAM-1 mRNA peaked at this time [57].
When all of the significant genes (with P<0.05) are considered, the most significantly
altered pathways are: MAPK signaling, focal adhesion, regulation of actin cytoskeleton,
cell cycle, and tight junction. MAPK signaling has been linked to many different cellular
events including, proliferation, senescence (a type of cell death), differentiation, and apop-
tosis. Focal adhesions are altered in response to changes in the molecular composition
in a cells extracellular matrix environment, and have been linked to pathways that regulate
cell proliferation, survival, migration and invasion. Actin is a component of every cells cy-
toskeleton, and regulates many cellular functions including muscle contraction, cell motility,
division and signaling, cytokinesis, vesicle movement, and the maintenance of cell junc-
tions and cell shape. The cell cycle is a series of events leading to cells replication. It has
been shown that the inhibition of the cell cycle is critical for many disease including cancer
and inflammation, however a proper cell cycle process is necessary for the recovery of
tissue following radiation. The tight junction pathway regulates the production of tight junc-
tion proteins, including claudin-5 and occludin, that are responsible for maintaining the firm
adherence of consecutive endothelial cells along the vasculature of the brain, a prominent
characteristic of the blood-brain barrier. The disruption of the tight junctions is a known
cause for the observed increase in BBB permeability following cranial irradiation.
6.2 Paracrine response
A paracrine response is when a substance secreted by one cell acts on adjacent
cells. A common example of a paracrine response in the brain is the inflammatory/immune
response. Following radiation with a single dose of 20-Gy radiation localized to the brain,
there are 36 genes that are significantly modulated (Table 6.2) and involved in the inflam-
matory/immune response. From these genes, it can be seen that the cytokine-cytokine
receptor interaction pathway (Table 6.3) is the most altered, with seven genes being al-
tered. All seven of the genes are classified as cytokines, with six classified as chemotactic
cytokines, or chemokines. A main responsibility of chemokines is to guide the migration
of response cells to the source of the chemokine. This is done by creating a chemotaxic
chemokine gradient. In other words, the chemokines that are released by the damaged
cells form a concentration gradient of chemokines, allowing the responding cells to use
the gradient to find the source of damage. The chemokines that are modulated are pro-
inflammatory, and are known to be induced during an immune response in order to recruit
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Table 6.1: Significant genes by function/pathway.
# of Genes
System P<0.05 P<0.01
Genetic Information Processing
Transcription
RNA polymerase 3 0
Basal transcription factors 4 2
Translation
Ribosome 3 0
Aminoacyl-tRNA biosynthesis 1 0
Folding, Sorting and Degradation
Protein export 2 0
SNARE interactions in vesicular transport 1 1
Regulation of autophagy 1 1
Proteasome 1 1
Environmental Information Processing
Membrane Transport
ABC transporters 4 2
Signal Transduction
MAPK signaling pathway 33 6
Wnt signaling pathway 17 4
Notch signaling pathway 9 2
Hedgehog signaling pathway 3 1
TGF-beta signaling pathway 9 3
VEGF signaling pathway 5 1
Jak-STAT signaling pathway 14 5
Calcium signaling pathway 17 2
Phosphatidylinositol signaling system 6 2
mTOR signaling pathway 7 3
Signaling Molecules and Interaction
Neuroactive ligand-receptor interaction 12 4
Cytokine-cytokine receptor interaction 16 7
ECM-receptor interaction 3 0
Cell adhesion molecules (CAMs) 14 7
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Table 6.1: (continued).
# of Genes
System P<0.05 P<0.01
Cellular Processes
Cell Motility
Regulation of actin cytoskeleton 21 2
Cell Growth and Death
Cell cycle 19 4
Apoptosis 10 2
Cell Communication
Focal adhesion 21 6
Adherens junction 12 2
Tight junction 17 5
Gap junction 12 0
Endocrine System
Insulin signaling pathway 14 2
Adipocytokine signaling pathway 9 2
PPAR signaling pathway 6 1
GnRH signaling pathway 11 1
Immune System
Hematopoietic cell lineage 3 1
Complement and coagulation cascades 4 1
Toll-like receptor signaling pathway 12 7
Natural killer cell mediated cytotoxicity 10 3
Antigen processing and presentation 9 4
T cell receptor signaling pathway 12 5
B cell receptor signaling pathway 7 3
Fc epsilon RI signaling pathway 7 1
Leukocyte transendothelial migration 9 3
Nervous System
Long-term potentiation 9 3
Long-term depression 9 1
Sensory System
Olfactory transduction 2 0
Taste transduction 3 0
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Table 6.1: (continued).
# of Genes
System P<0.05 P<0.01
Development
Dorso-ventral axis formation 3 0
Axon guidance 16 9
Behavior
Circadian rhythm 2 0
Diseases
Cancers
Colorectal cancer 15 4
Pancreatic cancer 8 1
Glioma 15 3
Chronic myeloid leukemia 14 3
Neurodegenerative Diseases
Alzheimer’s disease 3 3
Parkinson’s disease 1 0
Amyotrophic lateral sclerosis (ALS) 3 0
Huntington’s disease 7 2
Dentatorubropallidoluysian atrophy 1 0
Prion diseases 2 0
Metabolic Disorders
Type I diabetes mellitus 4 3
Type II diabetes mellitus 3 0
Maturity onset diabetes of the young 2 1
Total Number of Genes 532 142
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Table 6.2: Paracrine response genes.
Entrez
Gene ID
Symbol FC P-value Name
103406 9130206
N08Rik
1.26 0.0428 RIKEN cDNA 9130206N08 gene
12526 Cd8b1 -1.35 0.00791 CD8 antigen, beta chain 1
12611 Cebpg -1.35 0.00249 CCAAT/enhancer binding protein (C/EBP),
gamma
12946 Crry 1.31 0.0298 complement receptor related protein
13610 Edg3 -1.28 0.0336 endothelial differentiation, sphingolipid
G-protein-coupled receptor, 3
14825 Cxcl1 4.84 0.00188 chemokine (C-X-C motif) ligand 1
14964 H2-D1 1.53 0.00849 histocompatibility 2, D region locus 1
14972 H2-K1 1.25 0.00245 histocompatibility 2, K1, K region
14980 H2-L 1.24 0.0156 histocompatibility 2, D region
15216 Hfe 1.18 0.022 hemochromatosis
15285 Hlxb9 1.31 0.0449 homeobox gene HB9
15531 Ndst1 1.19 0.0205 N-deacetylase/N-sulfotransferase (heparan
glucosaminyl) 1
15900 Irf8 -1.41 0.0263 interferon regulatory factor 8
15945 Cxcl10 2.07 0.00616 chemokine (C-X-C motif) ligand 10
16071 Igk-C 1.52 0.00281 immunoglobulin kappa chain, constant
region
16160 Il12b 1.30 0.00497 interleukin 12b
17084 Ly86 -1.41 0.011 lymphocyte antigen 86
17319 Mif 1.78 0.00832 macrophage migration inhibitory factor
17857 Mx1 1.53 0.0168 myxovirus (influenza virus) resistance 1
17969 Ncf1 1.23 0.00332 neutrophil cytosolic factor 1
18636 Cfp -2.04 0.00102 complement factor properdin
20293 Ccl12 6.96 0.00148 chemokine (C-C motif) ligand 12
20296 Ccl2 1.6 0.00123 chemokine (C-C motif) ligand 2
20300 Ccl25 -1.19 0.0373 chemokine (C-C motif) ligand 25
20315 Cxcl12 -1.56 0.00135 chemokine (C-X-C motif) ligand 12
22637 Zap70 1.18 0.0471 zeta-chain (TCR) associated protein kinase
22695 Zfp36 1.63 8.39e-05 zinc finger protein 36
24088 Tlr2 1.65 0.00744 toll-like receptor 2
27205 Podxl -1.12 0.0156 podocalyxin-like
330122 Gm1960 4.09 0.00683 gene model 1960, (NCBI)
56298 Arl6ip2 1.22 0.0201 ADP-ribosylation factor-like 6 interacting
protein 2
56480 Tbk1 1.50 0.0305 TANK-binding kinase 1
630509 H2-Q7 1.49 0.0186 similar to H-2 class I histocompatibility
antigen, Q7 alpha chain precursor
71735 1200011
O22Rik
-1.67 0.00539 RIKEN cDNA 1200011O22 gene
72699 Lime1 -1.25 0.00332 Lck interacting transmembrane adaptor 1
80859 Nfkbiz 1.68 0.019 nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, zeta
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Table 6.3: Paracrine response pathways.
KEGG Pathway # of Genes Entrez Gene IDs
Cytokine-cytokine receptor
interaction
7 14825 15945 16160 20293 20296
20300 20315
Toll-like receptor signaling
pathway
4 15945 16160 24088 56480
Type I diabetes mellitus 3 14964 14972 16160
Natural killer cell mediated
cytotoxicity
3 14964 14972 22637
Cell adhesion molecules
(CAMs)
3 12526 14964 14972
Antigen processing and
presentation
3 12526 14964 14972
Leukocyte transendothelial
migration
2 17969 20315
T cell receptor signaling
pathway
2 12526 22637
Hematopoietic cell lineage 1 12526
Jak-STAT signaling pathway 1 16160
Complement and coagulation
cascades
1 12946
Axon guidance 1 20315
Neuroactive ligand-receptor
interaction
1 13610
Glycan structures -
biosynthesis 1
1 15531
Heparan sulfate biosynthesis 1 15531
Maturity onset diabetes of the
young
1 15285
Tyrosine metabolism 1 17319
Phenylalanine metabolism 1 17319
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immune cells to a site of damage. The chemokines are known to be chemoattractants for
leukocytes, monocytes, and neutrophils, a well as other effector cells.
Of the six chemokines, Ccl12 (Chemokine (C-C motif) ligand 12) and Cxcl1 (Chemokine
(C-X-C motif) ligand 1) have the largest increase at 2-hrs after radiation. Ccl12 showed a
fold change of 6.96, while Cxcl1 showed a fold change of 4.84 over the unirradiated. It
is thought, that Ccl12 coordinates movement of eosinophils, monocytes, and lymphocytes
during an immune response [135]. Cxcl1 has been shown to be a chemoattractant for
neutrophils, and to be involved in the processes of inflammation, wound healing, and an-
giogenesis. In addition, Cxcl1 has been shown to control the positioning of oligodendrocyte
precursors in the developing spinal cord by stopping controlling their migration [136].
6.3 Vascular versus parenchymal
Distinguishing the difference between vascular and parenchymal response is very
difficult because ultimately they are entwined with one effecting the other. However, there
are specific responses that are predominantly observed in each of the two populations.
Tables 6.4 and 6.5 show genes that are directly related to vessels/vasculature and neurons,
respectively. The breakdown of these genes into functional KEGG pathways is shown in
Tables 6.6 and 6.7. There were significantly altered 18 genes identified as part of the
vascular response and 36 identified as part of the parenchymal response. Of the genes
identified for the vascualr response, the predominate pathways altered were cell adhesion
molecules and leukocyte transendothelial migration. In the genes identified as part of
the parenchymal response, the most altered pathways were: neuroactive ligand-receptor
interaction, MAPK signaling, and axon guidance. Two genes of interest from these groups
are Pdgfra (platelet derived growth factor receptor, alpha polypeptide) from the vascular
response and Hes5 (hairy and enhancer of split 5) from the parenchymal response.
Pdgfra is a growth factor that regulates cell growth and division. It also been shown to
be important in the formation of blood vessels (angiogenesis), as well as cell migration and
cell proliferation. When pdgfra is activated, it has been shown to activate several signal
transduction pathways including MAPK and PI3K. Following cranial radiation, MAPK has
the largest number of significantly altered genes. At 2-hrs after cranial radiation, pdgfra
had a fold change of 1.48.
Hes 5, along with Hes 1 and Hes 3, has been shown to affect the differentiation pat-
terns of neuronal stem cells. Hatakeyama et al have shown that the Hes genes are critical
to the proper development (i.e., size, shape, and cell arrangement) of brain structures by
controlling when neuronal stem cells differentiate. At 2-hrs after cranial radiation, the Hes
5 gene had a fold change of -2.22. If this gene is down-regulated, it could have a significant
impact in a developing brain.
6.4 Early signs of neurostructural changes
Numerous studies have shown that years out from cranial radiation, patients experi-
ence neurological deficits. This is in part due to necrosis of both the white and gray matter,
78
Table 6.4: Genes related to the response of the vasculature.
Entrez
Gene ID
Symbol FC P-value Name
107746 Rapgef1 1.21 0.0207 Rap guanine nucleotide exchange factor
(GEF) 1
11998 Avp -1.15 0.0347 arginine vasopressin
12387 Ctnnb1 1.63 0.0249 catenin (cadherin associated protein), beta 1
15214 Hey2 -1.35 0.0146 hairy/enhancer-of-split related with YRPW
motif 2
16007 Cyr61 2.76 0.000207 cysteine rich protein 61
17123 Madcam1 -1.43 0.0215 mucosal vascular addressin cell adhesion
molecule 1
17967 Ncam1 -1.67 0.003 neural cell adhesion molecule 1
18007 Neo1 -1.32 0.0363 neogenin
18186 Nrp1 -1.41 0.00267 neuropilin 1
18212 Ntrk2 -1.47 0.00595 neurotrophic tyrosine kinase, receptor, type
2
18595 Pdgfra 1.48 0.0192 platelet derived growth factor receptor, alpha
polypeptide
19317 Qk -1.64 0.00963 quaking
20315 Cxcl12 -1.56 0.00135 chemokine (C-X-C motif) ligand 12
218397 Rasa1 -1.22 0.0276 RAS p21 protein activator 1
22329 Vcam1 1.26 0.0365 vascular cell adhesion molecule 1
56458 Foxo1 1.19 0.00517 forkhead box O1
56632 Sphk2 -1.33 0.0133 sphingosine kinase 2
67916 Ppap2b -1.37 0.018 phosphatidic acid phosphatase type 2B
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Table 6.5: Genes related to the response of the parenchyma.
Entrez
Gene ID
Symbol FC P-value Name
107934 Celsr3 -1.23 0.0245 cadherin EGF LAG seven-pass G-type
receptor 3
109648 Npy -1.33 0.0449 neuropeptide Y
11441 Chrna7 1.39 0.0376 cholinergic receptor, nicotinic, alpha
polypeptide 7
116837 Rims1 -1.28 0.0107 regulating synaptic membrane
exocytosis 1
11820 App -2.08 0.00772 amyloid beta (A4) precursor protein
11906 Atbf1 -1.25 0.0259 AT motif binding factor 1
11998 Avp -1.12 0.0347 arginine vasopressin
12064 Bdnf -1.45 0.0278 brain derived neurotrophic factor
12394 Runx1 1.32 0.042 runt related transcription factor 1
12426 Cckbr -1.35 0.0092 cholecystokinin B receptor
12608 Cebpb 1.38 0.0408 CCAAT/enhancer binding protein
(C/EBP), beta
12704 Cit -1.19 0.0355 citron
13175 Dcamkl1 1.54 0.0436 doublecortin and
calcium/calmodulin-dependent protein
kinase-like 1
13176 Dcc -1.64 0.00485 deleted in colorectal carcinoma
13385 Dlgh4 1.84 0.0027 discs, large homolog 4 (Drosophila)
13797 Emx2 -1.23 0.0212 empty spiracles homolog 2
(Drosophila)
140919 Slc17a6 1.51 0.0371 solute carrier family 17
(sodium-dependent inorganic
phosphate cotransporter), member 6
14291 Fpr-rs4 1.17 0.0474 formyl peptide receptor, related
sequence 4
14395 Gabra2 -1.47 0.0329 gamma-aminobutyric acid (GABA-A)
receptor, subunit alpha 2
15208 Hes5 -2.22 0.000678 hairy and enhancer of split 5
(Drosophila)
170757 Eltd1 1.12 0.0382 EGF, latrophilin seven transmembrane
domain containing 1
18189 Nrxn1 1.72 0.033 neurexin I
18222 Numb -1.75 0.00514 numb gene homolog (Drosophila)
18227 Nr4a2 -1.61 0.037 nuclear receptor subfamily 4, group A,
member 2
192678 Rassf3 1.23 0.0319 Ras association (RalGDS/AF-6)
domain family 3
19732 Rgl2 -1.19 0.0302 ral guanine nucleotide dissociation
stimulator-like 2
19877 Rock1 -1.25 0.0459 Rho-associated coiled-coil containing
protein kinase 1
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Table 6.5: (continued).
Entrez
Gene ID
Symbol FC P-value Name
20320 Nptn -1.27 0.0479 neuroplastin
20979 Syt1 -1.33 0.0128 synaptotagmin I
215690 Nav1 -1.23 0.00842 neuron navigator 1
21812 Tgfbr1 1.25 0.0273 transforming growth factor, beta
receptor I
218397 Rasa1 -1.22 0.0276 RAS p21 protein activator 1
21974 Top2b 1.70 0.0344 topoisomerase (DNA) II beta
225870 Rin1 -1.14 0.0401 Ras and Rab interactor 1
319387 Lphn3 1.36 0.00477 latrophilin 3
381677 Vgf -1.25 0.0053 VGF nerve growth factor inducible
Table 6.6: Pathway classification of the genes related to the vascular response.
KEGG pPathway # of Genes Entrez Gene IDs
Cell adhesion molecules
(CAMs)
4 17123 17967 18007 22329
Leukocyte transendothelial
migration
3 12387 20315 22329
MAPK signaling pathway 3 18212 18595 218397
Focal adhesion 3 107746 12387 18595
Axon guidance 3 18186 20315 218397
Colorectal cancer 2 12387 18595
Cytokine-cytokine receptor
interaction
2 18595 20315
Sphingolipid metabolism 2 56632 67916
Insulin signaling pathway 2 107746 56458
Calcium signaling pathway 2 18595 56632
Huntington’s disease 1 218397
Regulation of actin
cytoskeleton
1 18595
Gap junction 1 18595
Tight junction 1 12387
Adherens junction 1 12387
VEGF signaling pathway 1 56632
Wnt signaling pathway 1 12387
Neuroactive ligand-receptor
interaction
1 11998
Ether lipid metabolism 1 67916
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Table 6.7: Pathway classification of the genes related to the parenchymal response.
KEGG Pathway # of Genes Entrez Gene IDs
Neuroactive ligand-receptor interaction 4 109648 11998 12426 14395
MAPK signaling pathway 3 12064 21812 218397
Axon guidance 3 13176 19877 218397
Chronic myeloid leukemia 2 12394 21812
Calcium signaling pathway 2 11441 12426
TGF-beta signaling pathway 2 19877 21812
Huntington’s disease 2 12064 218397
Colorectal cancer 2 13176 21812
Notch signaling pathway 2 15208 18222
Pancreatic cancer 1 21812
Alzheimer’s disease 1 11820
Adipocytokine signaling pathway 1 109648
Regulation of actin cytoskeleton 1 19877
Leukocyte transendothelial migration 1 19877
Adherens junction 1 21812
Wnt signaling pathway 1 19877
Cytokine-cytokine receptor interaction 1 21812
Neurodegenerative Disorders 1 11820
Focal adhesion 1 19877
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vasculopathy, and the inhibition of neurogenesis. Clinically, signs are not seen until months
to years following radiation therapy, however by looking at the changes in gene expression
acutely after radiation, we can see that there are neurostructural changes in the acute
phase that could potentially be a cause for the late changes. By evaluating these changes
further, there is the potential for therapeutic intervention in the early stage that could reduce
the long-term effects. Table 6.8 shows the genes that are significantly different 2-hrs after
radiation and are known to be related to developmental and neurodegenerative diseases.
There are 34 genes that are significantly altered compared to the unirradiated.
One gene of interest related to neurodegenerative diseases, is amyloid precursor
protein (APP). At 2-hrs after a single dose of 20-Gy radiation, APP has a fold change of
-2.08. APP generates amyloid beta amino acid peptides, a main component of the amyloid
plaques found in Alzheimer’s disease. APP regulates many neuronal functions including
synapse formation, cell excitability, synaptic transmission, long-perm potentiation and cell
adhesion [137, 138, 139, 140, 141]. In Alzheimer’s disease, the amount of APP in a cell
decreases in proximity to an amyloid plaque and the decrease may contribute to dimentia,
a hallmark of Alzheimer’s disease. Recent work has also suggested that the level of APP
affects behavioral learning and memory[139, 140, 141].
6.5 Genes of interest
Out of the many genes evaluated at 2-hrs after cranial irradiation, there are some
genes of interest that were not included in the analysis above, but are of interest in their
relation to inflammation and/or radiation response. ICAM-1, which was investigated in
this work as a radiation-induced inflammatory molecule, showed a fold change of 2.53,
while GFAP (measured to evaluate astrocyte activation) had a fold change of 1.09. The
fold change of GFAP is not unexpected, as immunohistochemistry staining at 2-hrs after
radiation showed no significant increase in activated astrocytes. HIF-1α, a hypoxia marker
that is known to be up-regulated following radiation [142, 143, 144], showed a fold increase
of 1.89, while BCL-2 (B-cell leukemia/lymphoma 2) an anti-apoptotic molecule[145, 146],
was shown to be down-regulated (fold change of -1.43) at 2-hrs post-irradiation, which
correlates with the increase in p53 apoptosis observed following radiation. ATM (ataxia
telangiectasia mutated) is a gene that is commonly associated with radiation damage and
it has been shown that cellular radiosensitivity is increased in its absence, only showed a
fold changes of 1.07 [147, 148, 149, 150]. This is not unexpected as the effects of ATM
have been seen following radiation without an actual alteration in the expression of ATM
[148, 150]. Another gene of interest is Arc (activity-regulated cytoskeletal-related gene),
which has been associated with learning and memory formation, and showed a fold change
of -3.97. Studies have shown that radiation can alter Arc expression and that this may
correlate with the learning deficits observed following cranial irradiation [151, 152, 153].
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Table 6.8: Modulated genes related to development and neurodegenerative diseases.
Entrez
Gene ID
Symbol FC P-value Name
108100 Baiap2 -1.25 0.0328 brain-specific angiogenesis inhibitor
1-associated protein 2
11820 App -2.08 0.00772 amyloid beta (A4) precursor protein
12043 Bcl2 -1.43 0.0259 B-cell leukemia/lymphoma 2
12064 Bdnf -1.45 0.0278 brain derived neurotrophic factor
12914 Crebbp -1.69 0.0125 CREB binding protein
13176 Dcc -1.64 0.00485 deleted in colorectal carcinoma
13649 Egfr -1.23 0.0342 epidermal growth factor receptor
13835 Epha1 1.31 0.0152 Eph receptor A1
13841 Epha7 1.48 0.00446 Eph receptor A7
140499 Ube2j2 1.20 0.0125 ubiquitin-conjugating enzyme E2, J2
homolog (yeast)
14270 Srgap2 -1.20 0.0143 SLIT-ROBO Rho GTPase activating protein 2
14828 Hspa5 -1.47 0.0119 heat shock 70kD protein 5
(glucose-regulated protein)
15194 Hdh 1.25 0.0319 Huntington disease gene homolog
16956 Lpl 1.41 0.00548 lipoprotein lipase
16971 Lrp1 -1.39 0.00421 low density lipoprotein receptor-related
protein 1
17973 Nck1 -1.33 0.00739 non-catalytic region of tyrosine kinase
adaptor protein 1
18176 Nras -1.19 0.0484 neuroblastoma ras oncogene
18186 Nrp1 -1.41 0.00267 neuropilin 1
20315 Cxcl12 -1.56 0.00135 chemokine (C-X-C motif) ligand 12
20346 Sema3a 1.49 0.00176 sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin)
3A
20348 Sema3c 1.19 0.0182 sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin)
3C
20564 Slit3 -1.54 0.00242 slit homolog 3 (Drosophila)
20662 Sos1 2.37 0.0227 Son of sevenless homolog 1 (Drosophila)
20832 Ssr4 -1.11 0.0393 signal sequence receptor, delta
215114 Hip1 -1.19 0.00738 huntingtin interacting protein 1
218397 Rasa1 -1.22 0.0276 RAS p21 protein activator 1
22253 Unc5c -1.23 0.0265 unc-5 homolog C (C. elegans)
23871 Ets1 -1.61 0.0289 E26 avian leukemia oncogene 1, 5’ domain
268902 Robo2 -1.23 0.0316 roundabout homolog 2 (Drosophila)
319713 Ablim3 -1.37 0.0121 actin binding LIM protein family, member 3
53323 Hip2 1.36 0.0447 huntingtin interacting protein 2
66725 Lrrk2 -1.19 0.0109 leucine-rich repeat kinase 2
67300 Cltc -1.30 0.00303 clathrin, heavy polypeptide (Hc)
74018 Als2 -1.20 0.0421 amyotrophic lateral sclerosis 2 (juvenile)
homolog (human)
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6.6 Cytokine analysis
The serum cytokine G-CSF (granulocyte colony-stimulating factor) showed a signifi-
cant difference at 15-days post-RT (P<0.05) compared to unirradiated, but not at any other
time point measured, see Table 6.9. TNF, VEGF, IL-6, and IL-10 did not show any sig-
nificant difference at any time point. In a recent study by Merchant et al, cytokines were
measured in an attempt to find a clinical biomarker that would predict normal tissue and
tumor response to post-operative radiation therapy, in children with ependymoma’s [154].
Figure 6.2 shows the correlation between treatment success and treatment failure by look-
ing at the levels of VEGF. This study by Merchant et al [154]shows that cytokines could
make a viable marker for evaluating radiation response even though the current study did
not show significant changes at the expected time points.
6.7 Discussion
This study generated the data to look at the gene expression profile in the mouse
brain at 2-hrs after 20-Gy localized cranial irradiation. The large amount of data generated
provides the opportunity for further analysis to be carried out, in addition to providing in-
sight into specific questions regarding early markers of radiation damage.
• Is there a paracrine response that occurs?
There is a paracrine response observed following cranial irradiation that is primarily
initiated by chemotactic cytokines through the cytokine-cytokine receptor interaction
pathway. It is also possible that serum cytokine measurements can be used in the
future as a clinical marker of radiation damage/outcome/prognosis.
• Can we distinguish between parenchymal and vascular damage?
The gene expression profiles show that there is damage to both vascular and parenchy-
mal damage following cranial irradiation, and thru the analysis performed using the
known functions of the genes, the separate response of the two regions can be dis-
tinguished.
• Are there early signs of neurostructural damage?
The results identify 34 genes that were significantly altered at 2-hrs post-irradiation
that are known to be related to neurological/neurodegenerative diseases. By identify-
ing these genes, we may begin to understand the underlying reason for the observed
cognitive deficits following irradiation that may be the key to limiting these deficits, if
properly treated.
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Table 6.9: Serum cytokine results.
Control 24 hrs 48 hrs 72 hrs 8 days 15 days
IL6 79 111 65 55 141 264
p-value .9951 1.0000 .9993 .9610 .4909
IL10 66 102 60 56 33 66
p-value .8242 .9992 .9975 .6430 1.0000
GCSF 133 776 81 160 784 1656
p-value .5257 1.0000 1.0000 .5926 .0269*
VEFG 99 99 106 107 93 114
p-value 1.0000 .9684 .9552 .9722 .6191
TNF 171 168 169 171 176 191
p-value 171 .9100 .9772 1.0000 .9311 .1449
Following RT, there was not a significant change in serum cytokines measured up to 15-
days post-RT, except in GCSF. * indicates a significant difference compared to control.
Figure 6.2: Use of cytokine levels as a clinical biomarker.
It was observed tht there is an association between the lack of treatment failure and declin-
ing serum VEGF concentration. The graph is a plot of the log VEGF by treatment failure.
The observations plotted are local sample mean and standard error. Graph from Merchant
et al. “Cytokine and Growth Factor Responses After Radiotherapy for Localized Ependy-
moma”, Int J Radiat Oncol Biol Phys, in print. Copyright (c) 2008 Elsevier, with permission
from the publisher.
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Chapter 7
Discussion
In this work, we investigated the role of the inflammatory molecules TNF and ICAM-1
in the acute response to localized cranial radiation and investigated the use of an interven-
tional therapy and its ability to abrogate this acute inflammatory response. We also eval-
uate the changes in the complete gene expression profile to verify a paracrine response,
to delineate the damage to the vasculature versus the parenchyma, and to identify early
signs of neurostructural damage following cranial radiation.
Our study shows that localized cranial radiation causes a measurable increase in
astrogliosis, vessel permeability, leukocyte adhesion, and arteriole vasoconstriction up to
48-hrs after a single dose of 20-Gy radiation that is abrogated when TNF or ICAM-1 is in-
hibited. We also show that KZ-41 has the ability to abrogate the vascular changes following
radiation, but does not have an effect on the astrocytic response. By evaluating the gene
expression profile, we can show that there is a paracrine response following radiation that
is primarily driven by chemokines, that there is both a vascular and parenchymal response,
and that there are multiple genes up-regulated by radiation that are known to be related to
neurodegenerative diseases.
7.1 Radiation-induced vascular changes
In the current work, we observed an increase in permeability of the BBB and in leuko-
cyte adhesion following radiation that is abrogated when treated with an anti-inflammatory
agent (Figures 4.1 and 4.2). Further, arteriole vasoconstriction was observed at 48-hrs
post-radiation that was inhibited with treatment (Figure 4.4). Previous studies, in rats,
have shown that irradiation induces an increase in BBB permeability that was abrogated
following treatment with ICAM-1 mAb [9]. In addition, Panes et al observed an increase
in extravasation of FITC-albumin at 6-hrs after radiation in a rat messenteric model [26].
Our present study shows that this increase in BBB permeability following radiation can
be abrogated if the inflammatory cytokine TNF or the adhesion molecule ICAM-1 is in-
hibited. This increased permeability is caused in part by endothelial cell damage, as ex-
pressed by changes in tight junction integrity, and by vesicle formation post-irradiation.
Radiation-induced damage to endothelial cells has been examined by several investiga-
tors [49, 50, 51] aiming to elucidate the role of this damage in initiating and/or sustaining
radiation side effects. In previous studies using electron microscopy we show that radia-
tion causes damage to the tight junctions [70], which is also connected to the observed
increase in BBB permeability. In addition, several studies, including our own, have shown
an increase in BBB permeability and an increase in the number of vesicles following frac-
tionated cranial irradiation [70, 71, 72].
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Leukocyte adhesion is known to be up-regulated following single dose radiation [9, 16,
26] and has been shown to be accompanied by an increase in BBB permeability. Yuan et
al have shown, using antibody-coated microspheres, that ICAM-1 is up-regulated following
cranial radiation and reduced when treated with the anti-inflammatory drug dexametha-
sone [16]. The number of adherent anti-ICAM1 microspheres was five and nine times
that of IgG at 24- and 48-hrs post-radiation, respectively, and returned to baseline 7 days
post-radiation [16]. It has also been shown that E-selectin, and P-selectin are up-regulated
following cranial irradiation [16, 26], which, in addition to ICAM-1, have been shown to be
up-regulated by TNF. In our study, we show that when treated with anti-TNF or anti-ICAM-
1, radiation-induced leukocyte adhesion can be abrogated, which shows that both of these
molecules play an active role in this process. We also show that there is a significant cor-
relation between the permeability of the BBB and leukocyte adhesion and that if one effect
is limited, the other will be reduced as well.
Our study also shows that radiation induces a decrease in arteriole diameter that is
mediated by TNF, as our rTNF results demonstrated. The mechanisms of vasoconstriction
are not completely understood, but include: alterations in calcium signaling from the as-
trocytes, changes in nitric oxide levels, constriction of the smooth muscle cells, hematocrit
variations, and over-proliferation of endothelial cells [81, 17, 82, 83, 84]. The reduction in
arteriole diameter observed correlates with a study by Ansari et al [155] who shows that at
72-hrs post-20-Gy radiation there is an increase in hypoxia, which can be inhibited when
treated with TNF mAb. The observed decrease in arteriole diameter at 48-hrs post- radi-
ation in our study could play a role in initiating the hypoxia that Ansari et al observed at
72-hrs post-radiation [155]. In addition, it has been shown that ionizing radiation can in-
duce changes in microvascular structure and function [10, 11, 156]. Previous studies have
shown [10, 156] that radiation significantly changes the structure and microhemodynamics
of capillaries in the hamster cremaster muscle: compared to age-matched controls at early
time points (3, 7, and 30 days post-irradiation). Vessel diameter significantly decreased
with age, red blood cell velocity was significantly less, capillary surface area decreased
and vessel hematocrit increased, and finally blood flow was significantly lower. At late time
points (60, 120, and 180 days post-irradiation) red blood cell flux, red blood cell velocity
and capillary blood flow in networks at the 180 day time point were significantly larger than
age-matched controls. This indicates that the radiation-induced microvascular changes
are different in the late-term versus the acute, however, we believe that there is persistent
acute damage that eventually leads to the late-term effects.
To investigate the specific role of TNF in the observed irradiation-induced leukocyte
adhesion and changes in vessel diameter, rTNF was administered systemically. At 7-hrs
post-injection, there was a significant increase in leukocyte adhesion in both the venules
and arterioles, while at 24-hrs there was only a significant increase in arteriole adhesion.
Carvalho-Tavares et al observed similar increases in leukocyte adhesion in brain vascu-
lature with diameters between 50 and 120 µm following intraperitoneal administration of
TNF [157], while Wright et al observed an increase in leukocyte infiltration at the site of
an intracerebral injection of human rTNF in rats [158]. In our study we did not observe
any leukocyte adhesion in the cerebral arterioles following radiation treatment. This is in
contrast to a study by Acker et al who, in rats, indicates that arterioles show more leuko-
cyte adhesion than venules following collimated cranial irradiation [159]. The difference
in results between the present study, and that by Acker et al [159] could be explained by
the difference in the size of the arterioles measured. The diameter of the arterioles mea-
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sured by Acker et al was almost twice the size measured in the current study, as it was
in rats rather than mice. Outside of the brain, adhesion activity is often seen in arterioles,
but with a difference observed between diameters, with larger arterioles having more ad-
hesion than smaller arterioles [160, 161]. In addition, Mayhan used a rat open window
model, to show that the presence of TNF, via topical suffusion, did not affect arteriole di-
ameters [162]. Our study disagrees with this finding. The difference in findings is most
likely due to topical versus systemic administration of rTNF. We believe that systemic ad-
ministration is more relevant for comparison to elucidate the role of TNF in the observed
radiation-induced arteriole diameter changes.
By inhibiting TNF and ICAM-1, we are attempting to modulate the initial inflamma-
tory response that is created following radiotherapy, in an attempt to reduce the vascular
damage and activated astrocytes associated with radiation treatment. By successfully ab-
rogating these changes when treated, we show that these two molecules are at least partly
responsible for radiation-induced permeability, leukocyte adhesion changes, and arteriole
diameter changes, and are good targets for limiting this damage.
7.2 Histology
Our data shows that there is a significant increase in activated astrocytes up to 48-
hrs post-radiation and that when treated with radiation and anti-TNF or radiation and anti-
ICAM-1, the amount of activated astrocytes is significantly lower (Figure 4.6). In addition,
we show that there is a significant difference in the amount of activated astrocytes following
radiation when treated with anti-TNF versus anti-ICAM-1. This could imply that there is a
signal, possibly NF-κB, above ICAM-1 in the TNF pathway that stimulates the activation of
the astrocytes. Others have also shown that radiation causes an inflammatory response in
the parenchyma through the activation [47] of astrocytes and microglial cells [163, 152, 69].
With a single dose of 15-Gy, Hwang et al. showed that signs of radiation induced activated
astrocytes could be seen as early as 6-hrs post-radiation, though not significant until 24-
hrs post-radiation [69]. In vitro, Kyrkandies et al show that the irradiating of astrocytes
can significantly induce astrocyte activation as early as 4-hrs post-radiation accompanied
by an increase in TNF and IL-1β mRNA [58]. In a fractionated radiation model (2-Gy/day
for 4 weeks for a total of 40-Gy), astrocyte activation was delayed until 60 days from the
start of radiation, but remained significantly increased through 180 days [70]. Activated
astrocytes have been shown to have both positive and negative effects in the brain. It has
been shown that reactive astrocytes protect neurons from oxidative stress and play a cru-
cial role in the antioxidant defense in the brain via a glutathione dependent mechanism,
but also inhibit CNS regeneration and neurogenesis. Previous studies have shown that
after CNS injury, the presence of activated astrocytes can inhibit cell proliferation and neu-
roregeneration [164, 165], and that prolonged activation of astrocytes can create glial scar
sites which has been theorized to inhibit axonal regeneration or remyelination [166, 167].
Whether radiation-induced astrocyte activation is caused by direct ionization damage or
due to the breach in the BBB exposing the parenchyma to noxious substances and inflam-
matory cytokines is unclear. However, activated astrocytes have been shown to secrete
inflammatory agents [98, 97] which, in turn, could amplify microvascular damage. Protect-
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ing the astrocytes from radiation-induced damage may be a key factor in limiting long-term
damage in the brain.
We and others have shown that radiation induces the gene expression of TNF and
ICAM-1 in the brain [56, 57, 168]. Binding of TNF to its receptors on the endothelial cell
surface has been implicated in the activation of NF-κB, which in turn switches on the syn-
thesis of adhesion glycoproteins such as ICAM-1 [80]. ICAM-1 up-regulation can cause
increased leukocyte endothelial cell interactions triggering cytoskeletal remodeling, which
can be accompanied by paracellular transport [169, 170, 26, 9]. Our immunofluorescence
studies show that TNF protein levels are elevated at 24- and 48-hrs post-radiation accom-
panied by an increase in ICAM-1 protein levels. Treatment with radiation and anti-TNF
resulted in no expression of TNF protein and minimal expression of ICAM-1 protein. Treat-
ment with radiation and anti-ICAM resulted in no expression of ICAM-1, but some expres-
sion of TNF. This is because TNF expression can be stimulated by molecules other than
ICAM-1, such as NF-κB. Therefore, blocking ICAM-1 does not imply that TNF expression
levels will be affected. In addition, by administering rTNF, we show that TNF can induce the
protein expression of both TNF and ICAM-1. The detection of the increase in protein levels
of these two inflammatory molecules has an added significance over the previous findings
which were measurements of mRNA levels. Further, these results could offer a mechanis-
tic explanation for the observed increase in BBB permeability and the subsequent inhibition
of this increase following treatment with anti-TNF or anti-ICAM-1 and the resulting protein
expression levels.
7.3 The role of TNF
We have shown that TNF is involved in and is capable of producing the observed
acute effects following radiation. We achieve this in two different ways: first, by induc-
ing the effects of TNF by administering recombinant TNF and second, by irradiating and
treating with an antibody to TNF hence inhibiting the effect of TNF. The recombinant TNF
showed that leukocyte adhesion, arteriole diameter changes and astrogliosis can be in-
duced by TNF as early as 7-hrs after 0.5µg rTNF. By irradiating and treating with anti-TNF,
we show that the observed effects induced by irradiation (BBB permeability, leukocyte ad-
hesion, arteriole diameter changes, and astrogliosis) can be abrogated if TNF is inhibited.
This shows that there is an acute inflammatory response initiated when localized cranial
irradiation is given, and that TNF is a key factor in this response. Currently in the clinic,
there are inhibitors to TNF being used to treat chronic inflammatory diseases and autoim-
mune disorders such as, rheumatoid arthritis, Crohn’s disease, psoriasis, and ankylosing
spondylitis. Two of these inhibitors are monoclonal antibody-based, infliximab and adal-
imumab, while the other is a receptor fusion protein, etanercept [171, 172]. In addition,
several anti-TNF agents have been studied for their anti-tumor activity including infliximab,
thalidomide, and lenalidomide [173, 174, 175]. Infliximab has been used in rheumatoid
arthritis and has recently showed clinical efficacy in a phase II trial against renal cell carci-
noma [173]. Thalidomide is a derivative of glutamic acid which has anti-inflammatory and
angiogenic activities; it inhibits the production of TNF, VEGF, and decreases the binding
activity of NF-κB [176, 177] and is currently in a phase II trial for the treatment of recurrent
glioblastoma. Groves et al, show that the combination of temozolomide plus thalidomide
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was safe but with little improvement over temozolomide alone [178]. Lenalidomide or CC-
5013 is an analog of thalidomide that has shown increased potency in preclinical trials
against myelomas and fewer nonhematologic side effects [174, 175]. Both thalidomide
and lenalidomide show increased efficacy when used in combination with dexamethasone
albeit with higher risk of thrombosis that can be prevented with the use of aspirin [174, 179].
Thalidomide and lenalidomide are small molecules [180] that can cross the BBB in thera-
peutic quantities and have been shown to significantly increase survival and to decrease
motor neuron cell death in transgenic mice with amyotrophic lateral sclerosis symptoms
[181].
It is quite practical and probable that introducing the use of an anti-TNF drug to help
limit the radiation-induced damage will be evaluated in the future. This work shows that
TNF is a main component in the acute vascular damage following cranial radiation, and
that there is an inflammatory component to radiation damage that can be easily addressed.
With the numerous inhibitors of TNF already available, and the re-evaluation of anti-TNF
drugs as tumor treatments, the combination could prove promising. However, the length
of time in which TNF is inhibited must be controlled, as Daigle et al have shown that the
lack of the TNF p75 receptor following cranial radiation can exacerbate radiation-induced
demyelination, in both severity and in location of myelin loss [66].
7.4 KZ-41
KZ-41 is a novel drug derived from quinic acid that preliminary studies have shown
to be a potent anti-inflammatory agent. In vitro studies have indicated that KZ-41 acts
through the NF-κB pathway. Our in vivo studies show that KZ-41 has the ability to reduce
radiation-induced inflammation in the brain following localized cranial irradiation having a
similar effect to that of pure antibodies to TNF and ICAM-1. KZ-41 limits radiation-induced
increases in BBB permeability, leukocyte adhesion, and arteriole diameter changes. It
also limits the expression of TNF and ICAM-1 protein. It does not however inhibit radiation-
induced astrogliosis. In fact it actually appears to act as a radiosensitizer to the astrocytes
making them more sensitive to the damage from radiation. This is a very interesting char-
acteristic. This is a drug that can protect the vasculature from radiation-induced damage
while at the same time increase the sensitivity of parenchymal cells to radiation.
Other studies have shown that nonsteroidal anti-inflammatory drugs (NSAIDs), such
as ibuprofen, enhance the sensitivity of cells to radiation [182, 183, 184]. The mechanism
by which NSAIDs act as radiosensitizers is not fully understood, however, Palayoor et al
have shown that ibuprofen can reduce hypoxia-inducible factors HIF-1α and HIF-2α [183].
The state of hypoxia creates a shortage of oxygen free radicals, which is primarily how
ionizing radiation damages DNA, so by inhibiting the hypoxic state, there is more of a
chance for the cells to be damaged by radiation. At this time, it is unclear why only the
astrocytes responded to the radiosensitizing effects of KZ-41.
Treatment with KZ-41 in conjunction with radiation was different than specific antibody
treatments with radiation. This indicates that a broad spectrum anti-inflammatory inhibitor
may not be the optimum approach as an interventional therapy for radiation damage, and
a molecule/paathway specific approach should be considered. In addition, as shown using
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KZ-41, the in vivo and histological methods that have been developed in this work can be
used to screen drugs aimed at limiting the acute inflammatory response following cranial
radiation.
7.5 Early markers of radiation-induced damage
7.5.1 Gene expression
Each microarray chip that was analyzed contained 45,101 different genes. By evalu-
ating the changes in expression of these genes we have begun a comprehensive analysis
of radiation effects at the very basic level. There is a wealth of information that has been
generated and there is much analysis to be carried out, but as can be seen from the
genes presented, having this data will allow us to investigate the changes occurring at the
mRNA level to better understand where the observed damage is coming from. A better
understanding of the initiation of the damage, will enable more focused studies into the
presentation of the damage as well as a method to prevent the damage from happening.
Our results show that there is a paracrine response to radiation that is initiated pri-
marily by chemotactic cytokines through the cytokine-cytokine receptor interaction path-
way. These are pro-inflammatory chemokines that are known to recruit immune cells to
sites of damage. The identification of an inflammatory response at the gene level indi-
cates that there is an acute inflammatory state that is created following a single dose of
cranial irradiation, which could be a target for interventional therapy. Our results also al-
low us to delineate the damage to the vasculature from the parenchymal damage. Since
our overall hypothesis is that the vasculature is a major source of damage (early and late-
term), identifying markers of this damage will provide a method for a targeted approach for
monitoring vasculature damage following radiation. Our results show that there are genes
that are known to be related to neurological/neurodegenerative diseases that become up-
regulated in the acute phase following radiation. It is possible that the alteration in these
genes may be the underlying reason for the cognitive deficits following radiation, and if
treated properly, may be the key to limiting these deficits.
A main hypothesis of this work in general is that limiting/eliminating the acute damage
will minimize long-term damage following radiation, especially the cognitive damage. One
gene that was down-regulated (fold change -2.08) following radiation and also to be related
to a neurodegenerative condition is APP. As previously stated, APP (amyloid precursor
protein) is known to generate amyloid beta amino acid peptides, a main component of the
amyloid plaques found in Alzheimer’s disease. There is currently an agent (memantine)
being explored to limit the radiation-induced cognitive deficits, a neurodegenerative effect,
that has been shown effective in improving cognitive impairment in Alzheimer’s patients.
Memantine is a non-competitive N-methyl-D-aspartate receptor antagonist, that works by
inhibiting the overstimulation of glutamate [185]. In Alzheimer’s patients with mild to mod-
erate vascular dementia or moderate to severe Alzheimer’s type dementia, memantine has
been shown to improve cognition [186, 187, 188]. Other treatments that have been tested
for neuronal protection following cranial radiation include lithium and podophyllum hexan-
drum. If steps can be taken to replace the levels of APP this could potentially be one way
to limit cognitive deficits following radiation.
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7.5.2 Serum cytokines
Damage to the blood-brain barrier is most likely to trigger a systemic response in the
body’s efforts to recover. Circulating cytokines could indicate the level of such response
and might allow us to elucidate the mechanisms triggered by the localized damage induced
by radiation. In our experiments, the serum cytokine GCSF was the only cytokine that
showed a significant increase following irradiation treatment localized to the brain. The cy-
tokine GCSF is involved in stimulating the production of and the recruitment of neutrophils,
which then migrate to the site of inflammation. GCSF was only elevated at 15-days post-
RT indicating a late response to irradiation damage. This might indicate that the majority
of the irradiation-induced inflammatory response is limited to the immediate vicinity, rather
than circulating in the serum. In addition, as shown by Merchant et al [154], cytokine levels
can be used to predict the outcome of patients following CNS radiation, and if explored
further could provide a way to monitor patients following radiation and give interventional
therapies accordingly.
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Chapter 8
Conclusions and Future Work
8.1 Conclusions
The goal of the current work was to elucidate the role of the inflammatory response in
the initiation and propagation of the acute microvasculature changes, following cranial irra-
diation, by evaluating the role of TNF. This work also investigated a novel anti-inflammatory
agent, KZ-41, for use as a potential interventional therapy in preventing the radiation-
induced inflammatory response. In addition, this work generated the gene profile of the
mouse brain in order to characterize the acute damage following radiation. The main con-
clusions from this work are the following:
• A single dose of 20-Gy cranial irradiation induces the expression of the inflammatory
molecules TNF and ICAM-1 in the brain at 24- and 48-hrs after irradiation.
• The inhibition of TNF or ICAM-1 via antibodies given in conjunction with radiation can
abrogate the radiation-induced inflammatory response.
• TNF plays a bigger role in radiation-induced inflammation than ICAM-1, and as such,
its inhibition is more potent.
• The anti-inflammatory agent KZ-41 can inhibit radiation-induced vascular effects, but
acts as a sensitizer to astrocytes similar to other NSAID’s.
• There is a significant increase in astrogliosis following radiation that could persist
and be a key factor in long-term damage, and that appears to be related to the
inflammatory state in the brain.
• There are early markers of inflammation and damage in the brain occurring at the
gene level that may be responsible for the late effects observed following radiation.
• Techniques were established to evaluate mRNA and protein expression that, in con-
junction with our in vivo measurements, gives us the tools to begin answering mech-
anistic questions about what is happening in the brain following cranial irradiation and
ways to intervene.
8.2 Future Work
Understanding the effects that radiation has on the vasculature of the brain, and the
role that the inflammatory response plays is key to limiting late-term radiation damage.
The current work investigated the role of TNF and ICAM-1 as the mechanisms thru which
radiation-induced inflammation occurs. The modulation of either molecule, via specific an-
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tibodies, inhibited the inflammation-associated radiation-induced vascular responses. A
novel anti-inflammatory agent, KZ-41 was investigated as an interventional therapy, but
showed that the broad inhibition of the inflammatory response may not be optimal. In ad-
dition, gene expression data was generated that will provide more, comprehensive insight
to the changes that are occurring immediately following radiation. Although the current
studies have identified some mechanisms thru which radiation-induced damage happens,
further work needs to be done. Below are some of the potential future studies to continue
to understand radiation damage to the brain.
The mechanism of increases in BBB permeability following cranial irradiation is thought
to be alterations in the tight junctions and vesicle formation. In previous studies, electron
microscopy and histology were used to evaluate the endothelial cells and their response fol-
lowing radiation. The current study showed that inhibiting the expression of TNF or ICAM-1
abrogated the radiation-induced changes in BBB permeability, however the mechanism by
which this occurs is unclear. To elucidate the mechanism by which this is happening, one
could look at the expression of cytoskeletal proteins before and after irradiation, with and
without treatment. One could also evaluate the changes in cytoskeletal protein expression
at early time points and late time points, to relate the early vascular changes to late-term
changes.
The current work focused on the acute changes to the vasculature in response to
radiation, but did not address the late-term changes. There exists a controversy in the field
of radiation research about whether a relationship exists between the early effects from
radiation and the long-term effects of radiation. We hypothesize that abrogating the early
damage will limit the late-term damage, but to test this, one needs to treat during the acute
phase, and then evaluate the vascular parameters at the late time points. The current work
shows that TNF would be an effective target to evaluate this hypothesis.
KZ-41 is a novel agent that is thought to work thru the NF-κB pathway, which is known
to up-regulate ICAM-1. When KZ-41 was administered, the vascular effects of radiation
were inhibited, but the astrocytic response was amplified. The mechanism by which KZ-41
affected the astrocytes is unknown, and is a point of interest for further research. A future
study could evaluate the effectiveness of a known NF-κB inhibitor in comparison to KZ-
41. This would help elucidate the true effects of inhibiting NF-κB. If the specific inhibitor
showed the same response as KZ-41, it could imply that the role NF-κB plays in radiation
damage is separate from its activation by the TNF pathway, and is not an effective target
for limiting radiation-induced damage.
Microarray analysis was used to evaluate the changes in gene expression at 2-hrs af-
ter a single dose of cranial irradiation. This study looked at the significantly altered genes
that are involved in the inflammatory, vascular and parenchymal responses, as well as gene
related to neurostructural alterations. The genes evaluated are but a small subset of the
genes observed to be significantly altered, so further analysis is needed to better under-
stand the changes occurring. In addition, the generated data is from animals with radiation
only. Future work could evaluate the gene expression changes in animals that are treated
with radiation and TNF or ICAM-1 antibodies. The would allow for the evaluation of the shift
in gene expression induced by the inhibition of the acute inflammatory response following
radiation, to better understand what role inflammation is playing in radiation-induced dam-
age. In addition, evaluating the alterations in the gene expression in both radiation-only
95
and radiation and TNF or ICAM-1 antibody treated groups at late time points could help
relate the acute radiation changes to late radiation changes.
The current study administered radiation locally to a strip of brain, with lead body
shielding to ensure that other areas did not receive a measurable radiation dose. It is
possible to control radiation exposure, but the biological response to radiation may not
be limited to the irradiated tissue, especially in the case of cytokines, which are released
into the blood stream. This work measured serum cytokine levels at various time points
after 20-Gy radiation, but only showed a significant difference in one cytokine (GCSF) at
one time point (15-days post-irradiation). It is possible that there were experimental errors
(such as the time of day the blood was collected and time between collection and serum
extraction) in the collection and analysis of this data, and suggest it be repeated to either
confirm these results or generate different results. It is also suggested that other cytokines
be considered for analysis.
The animal model used in this work employed a cranial window to visualize the vas-
culature of the brain. This allows access to the superficial pial vessels of the brain. These
vessels are sufficient for evaluating the vasculature parameters we are interested in, as
they have been shown to possess the characteristics of the blood-brain barrier, but they
cannot provide a complete picture of what is happening in the brain. It would be very
beneficial if future studies could employ whole brain imaging technologies to evaluate the
effects of radiation on the brain as a whole rather that a small part, and be more clinically
relevant.
Understanding the effects of radiation on normal tissue is critical in limiting radiation
toxicity during treatment for brain tumors. However, it is known that the presence of a tumor
alters the well-controlled microenvironment of the brain, and as such, may effect the way
that normal tissue responds to radiation damage. It is essential that future studies include
a tumor to mimic the environment in the brain that is created with tumor presence. Any
treatment that has the ability to protect the normal tissue, including anti-TNF treatments,
must be evaluated with a tumor present to ensure that is does not reduce the efficacy of
radiation therapy.
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Appendix A
Cranial Window Surgery Protocol
Surgical tools
• Vannas Iridocapsulotomy Scissors
• Jeweler-Type Micro Forceps Curved
• Fine Scissors, Straight, S/S
• Dressing Forceps, Curved, Serr
Procedure
1. Anesthetize the animal.
2. Remove hair, using an electric shaver and/or hair removal lotion.
3. Apply eye ointment.
4. Secure the animal in the stereotaxic frame.
5. Disinfect the exposed skin using alcohol and betadine.
6. Use the Fine Scissors to remove the skin from the top of the head. Exposing the
bregma and lambdoid sutures and an adequate area to the sides of the midsaggital
suture for the window to be placed.
7. Use the Dressing Forceps and scissors to remove the fascia from the skull, leaving a
dry surface for drilling.
8. Use a dental drill to create a rectangular opening in the skull bone
9. Once the skull is off, always keep aCSF on the brain, applying frequently as it will be
absorbed.
10. Use a 301/2 gauge needle and the Vannas Iridocapsulotomy Scissors to excise the
dura mater.
11. Once the dura is removed, place the glass window over the opening (make sure
aCSF is added to the exposed brain prior to window placement.
12. Apply super glue to the window, using a 301/2 gauge needle, from glass to bone
starting in the center of each side and then filling in.
13. Allow the glue to sit for a few minutes before removing the animal from the stereotaxic
frame and placing in an isolated cage.
112
Table A.1: Artificial cerebral spinal fluid.
Solution* Components For 1liter (g) For 20X Stock** (g)
KCl 0.22 4.4
MgCl2.6H2O 0.305 6.1
A CaCl 0.264 5.28
NaCl 7.71 154.2
Urea 0.402 8.04
Dextrose 0.665 13.3
B NaHCO3 2.066 41.32
*- Prepare the solution A and B separately, and mix them together before experiments.
The final solution is filtered using 0.22 µm filter for perfusion.
**- For 20X stock solution, dilute 20 times and mix together.
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Appendix B
Immunofluorescence Staining Protocol
1. 2.5 minutes in 95% alcohol.
2. Wash in Distilled water.
3. Wash in PBS.
4. Incubate with 0.1X Triton for 5 minutes.
5. Wash in PBS.
6. Let slides air dry.
7. Use DAP pen to draw a circle around the tissue sections.
8. Wash in PBS x 5min x 3.
9. Incubate with 10% normal blocking serum in PBS for 20 minutes.
10. Wash in PBS x 5min x 3.
11. Incubate with primary antibody for 60 minutes (in 1.5% normal blocking serum).
12. Wash in PBS x 5min x 3.
13. Incubate with secondary antibody for 45 minutes (in 3% normal blocking serum).
14. Wash in PBS x 5min x 3.
15. Mount coverslips with aqueous mounting medium or 90% glycerol in PBS.
16. Examine with fluorescence microscope.
17. Store at room temperature (if mounted with aqueous mounting medium) or 4C (if
mounted with glycerol).
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